Study Title : 
Sponsor: 
IND Number : 
Eudra CT Number : 
Clinical Trial s.gov Identifier : 
Indication : 
Protocol ID: (rJ GILEAU 
CLINICAL STUDY PROTO COL 
A Phase lb Randomized , Doub le-Blinded , Placebo Controlled , 
Multi-Coho1t Study of the Safety , Phannaco kinetics , and Antiviral Activity 
ofGS-6207 administered subcutaneous ly in HIV-1 Infect ed Subjects 
Gilead Sciences , Inc. 
333 Lakeside Drive 
Foster City, CA 94404 
136260 
Not Applicable 
[STUDY_ID_REMOVED] 
HIV-1 Infection 
GS-US-200-4072 
Gilead Clinical Program Manager : Name: PPD 
PPU 
PPD Telephone: 
Fax: 
Gilead Medical Monitor : Name: 
Telephone: 
Fax: 
Cell: 
Gilead Clinical Study Director : Name : 
Telephone: 
Fax: 
Cell: 
Protocol Version/Date : Original: 
Amendment I: 
Amendment 2: 
Amendment 3: 
Amendment 4: PPD 
PPD 
PPD 
PPD 
PPD 
Pl'U 
PPD 
PPD 
14 Septemb er20l8 
20 December 2018 
13 March 2019 
21 May20l9 
13 June 2019 
CONFIDE NTIALITY STATEME NT 
The info1mation contained in this document, paiiicularly unpub lished data, is the prope 1iy or 
under control of Gil ead Sciences, Inc., and is provide d to you in confidence as an investigato r, 
potential investigator, or consultant, for review by you, your staff , and an applicable Institutional 
Review Board or Independent Ethics Committ ee. The infonnation is o nly to be u sed by you in 
connectio n with autho rized clinical studies of the investigational diug described in the protoco l. 
You will not disclose any of the infonnation to others without written a uthorizatio n from 
Gilead Sciences, Inc., except to the extent necess aiy to obtain infonned consent from those 
perso ns to whom the dmg may be adinini stered. 
GS-6207 and TAF 
Protocol GS-US -200-4072 
Gilead Sciences , Inc. Final 
Amendment4 
TABLE OF CONTE NTS 
TABL E OF CO NTENTS .......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ....... 2 
LIST OF IN-TEXT TABLES ............ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ....... 4 
LIST OF IN-TEXT FIGURES .......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ....... 5 
PROTOCO L SYN OPSIS .......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ....... 6 
GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS ............ ................ .......... ........ ................ ...... 13 
1. INTRODUCTI ON ............ ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 16 
1.1. Backgrowid .......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 16 
1.2. GS-6207 ............... ........ ........ ......... ........ ......... ........ ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 16 
1. 2 .1. Gene ral Infonnation ............ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 16 
1.2.2. Additiona l Clinica l Studies ......... ......... ........ ........ ......... ........ ......... ........ ........ ........ ......... ..... 17 
1.3. Tenofo vir alafenami de (TAF) ............... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 22 
1.3 .1. Gene ral Infonnation ............ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 22 
1.4. Rationale for this Study ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 23 
1.4.1. Rationale for the developmen t of GS-6207 .................. ................ .......... ........ ........ .............. 23 
1.4.2. Rationale for the development of weekly oral TAF .............. ................ ................ .......... ..... 24 
1.5. Rationale for the Dose Selec tion ........... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 24 
1.5.1. GS-6207 ............. ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 24 
1.5.2. TAF ............ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ......... ........ ..... 25 
1.6. Risk/Benefit Assessmen t for the Study ......... ......... ........ ........ ......... ........ ......... ........ ........ ........ ......... ..... 26 
1.7. Compliance .......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 26 
2. OB JECTIVES .......... ......... ........ ........ ......... ........ ......... ........ ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 27 
3. STUDY DES IGN .............. ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 28 
3.1. 
3.2. 
3.3. 
3.4. Endpoint s ............. ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 28 
Study Design ........ ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ......... ........ ..... 28 
Study Treatments ......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 28 
Duration of Treatment .......... ........ ......... ........ ........ ......... ......... ................ ........ ........ ......... ........ ........ ...... 30 
4. SUBJECT POPULAT ION ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 31 
4.1. Number of Subject s and Subjec t Selec tion .. .......... ........ ................ ................ .......... ........ ................ ...... 31 
4.2. Inclu sion Criteria (Paits A and B) ......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 31 
4.3. Exclusion Criteria (Part s A and B) ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 33 
5. INVESTIGATIO NAL MEDIC INAL P RODUCT AND B/F/TAF .............. ........ ................ ................ .......... ..... 34 
5.1. Randomiza tion, Blinding and Treatment Codes ............ ................ ................ .......... ........ ................ ...... 34 
5.1.1. Procedure s for Breaking Treatmen t Codes (Pait A) .............. ................ ................ .......... ..... 34 
5.2. Description and Handling GS-6207 , TAF and B/F/TAF ................ ........ ................ ........ .......... ........ ..... 35 
5.2.1. Foimulation ........ ......... ........ ........ ......... ........ ......... ........ ........ ........ ......... ........ ........ ......... ..... 35 
5.2.2. Packaging and Labe ling .............. ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 36 
5.2.3. Storage and Handling .......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 36 
5.3. Dosage and Admini strntion of GS-6207 (Pait A, Coho it s 1 - 5) .................... .......... ........ ................ ...... 37 
5.4. Dosage and Admini strntion ofTAF (Part B, Cohort s 6 - 8) .. .......... ........ ................ ................ .......... ..... 38 
5.5. Prior and Concomi tant Medica tions .............. ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 38 
5.6. Dispensing , Accowi tability, and Disposal or Return of GS-6207 and TAF (study dtug s) and 
B/F/TAF ............... ........ ........ ......... ........ ......... ........ ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 40 
CONFIDENTIAL Page2 13 Jwie 2019 
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 3 13 June 20196. STUDY PROCEDURES .................................................................................................................................... 41
6.1. Subject Enrollment and Treatment Assignment ..................................................................................... 41
6.2. Pretreatment Assessments ...................................................................................................................... 41
6.2.1. Screening Visit ..................................................................................................................... 41
6.3. Treatment Assessments .......................................................................................................................... 42
6.3.1. Day 1.................................................................................................................................... 42
6.3.2. Assessments on Days 2, 3, 4, 7, 8, 9, 10, 14, 29, 43, 57, 85, 113, 141, 169, 
197 and 225 .......................................................................................................................... 43
6.4. Early Study Discontinuation Assessments ............................................................................................. 43
6.5. Criteria for Discontinuation of Study ..................................................................................................... 44
6.6. Clinical Laboratory Assessments ........................................................................................................... 44
6.6.1. Blood Samples ...................................................................................................................... 45
6.6.2. Urine Samples ...................................................................................................................... 47
6.7. Management of Virologic Failure after Initiation of B/F/TAF on Day 10 ............................................. 47
6.7.1. Suboptimal Virologic Response (SVR) ................................................................................ 47
6.7.2. Virologic Rebound (VR) ...................................................................................................... 48
7. ADVERSE EVENTS AND T OXICITY MANAGEMENT ............................................................................... 49
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events ................................. 49
7.1.1. Adverse Events ..................................................................................................................... 49
7.1.2. Serio us Adverse Events ........................................................................................................ 49
7.2. Assessment of Adverse Events and Serious Adverse Events ................................................................. 50
7.2.1. Assessment of Causality for Study Drugs and Procedures ................................................... 50
7.2.2. Assessment of Severity ...............................................................
......................................... 51
7.3. Investigator Requirements and Instructions for Reporting Adverse Events and Serious 
Adverse Events to Gilead ....................................................................................................................... 51
7.4. Gilead Reporting Requirements ............................................................................................................. 53
7.5. Clinical Laboratory Abnormalities and Other Abnormal Assessments .................................................. 53
7.6. Toxicity Management ............................................................................................................................ 54
7.7. Special Situations Reports ...................................................................................................................... 54
7.7.1. Definitions of Special Situations ...............................................................
........................... 54
7.7.2. Instructions for Reporting Special Situations ....................................................................... 55
8. STATISTICAL CONSIDER ATIONS ................................................................................................................ 57
8.1. Analysis Objectives and Endpoints ........................................................................................................ 57
8.1.1. Analysis Objectives .............................................................................................................. 57
8.1.2. Primary Endpoint ................................................................................................................. 57
8.1.3. Secondary Endpoint ............................................................................................................. 58
8.1.4. Other Endpoints of Interest .................................................................................................. 58
8.2. Analysis Conventions ............................................................................................................................. 58
8.2.1. Analysis Sets ........................................................................................................................ 58
8.3. Data Handling Conventions ................................................................................................................... 59
8.4. Dem ographic Data and Baseline Characteristics ................................................................................... 59
8.5. Efficacy Analysis ................................................................................................................................... 59
8.5.1. Primary Analysis .................................................................................................................. 59
8.5.2. Secondary Analyses ...............................................................
.............................................. 60
8.6. Safety Analysis ....................................................................................................................................... 60
8.6.1. Duration of Exposure ........................................................................................................... 60
8.6.2. Adverse Events ..................................................................................................................... 60
8.6.3. Laboratory Evaluations ........................................................................................................ 60
8.6.4. Other Safety Evaluations ...................................................................................................... 61
CCI
CCI-
-
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 4 13 June 20198.7. Pharm acokinetic Analysis ...................................................................................................................... 61
8.8. Sample Size ............................................................................................................................................ 61
8.9. Analy sis Schedule ................................
.................................................................................................. 62
9. RESPONSIBILITIES .......................................................................................................................................... 63
9.1. Investigator Responsibilities .................................................................................................................. 63
9.1.1. Good Clinical Practice .......................................................................................................... 63
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Revie w and Approval ........................................................................................................... 63
9.1.3. Informed Consent ................................................................
................................................. 63
9.1.4. Confidentiality ...................................................................................................................... 64
9.1.5. Study Files and Retention of Records .................................................................................. 64
9.1.6. Case Report Forms ............................................................................................................... 65
9.1.7. GS-6207 and TAF (Investigational Medicinal Product or Study Drug) a nd 
B/F/TAF Accountability and Return .................................................................................... 66
9.1.8. Inspections ............................................................................................................................ 66
9.1.9. Protocol Compliance ............................................................................................................ 66
9.2. Sponsor Responsibilities ........................................................................................................................ 66
9.2.1. Protocol Modifications ......................................................................................................... 66
9.2.2. Study Report and Publications ............................................................................................. 67
9.3. Joint Investigator/Sponsor Responsibilities ........................................................................................... 67
9.3.1. Payment Reporting ............................................................................................................... 67
9.3.2. Access to Information for Monitoring .................................................................................. 67
9.3.3. Access to Information for Auditing or Inspections .............................................................. 68
9.3.4. Study Discontinuation .......................................................................................................... 68
10. REFERENCES ................................................................................................................................................... 69
11. APPENDICES .................................................................................................................................................... 70
Appendix 1. Investigator Signature Page .................................................................................................... 71
Appendix 2. Study Procedures Table .......................................................................................................... 72
Appendix 3. Management of Clinical and Laboratory Adverse Events ...................................................... 75
Appendix 4. GSI Grading Scale for Severity of Adverse Events a nd Laboratory Abnormalities ............... 76
Appendix 5. Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC Guidelines) ............................. 98
Appendix 6. GS-6207 Pregnancy Precautions (Part A), Definition for Female of Childbearing 
Potential, and Contraceptive Requirements ............................................................................ 99
Appendix 7. TAF Pregnancy Precautions (Part B), Definition for Female of Childbearing 
Potential, and Contraceptive Requirements .......................................................................... 101
LIST OF IN -TEXT TABLES
Table 1-1. Study GS -US-200
-4070 Preliminary Plasma Pharmacokinetic Parameters of 
GS-6207 Follow ing Single Dose Administration of Subcutaneous Suspension of 
GS-6207, 30 -450mg.............................................................................................................. 18
Table 1-2. Study GS -US-200
-4071 Preliminary Plasma Pharmacokinetic Parameters of 
GS-6207 Follow ing Single and Multiple Dose Oral Administration of 30 mg 
(50mg/mL) and 100 mg (50 mg/mL) ..................................................................................... 19
Table 1-3. Study GS -US-200
-4071 Preliminary Plasma Pharmacokinetic Parameters of 
GS-6207 Follow ing Single Dose Oral Administration in Cohorts 3 (300 mg, 
10mg/mL) and 4 (7 mg, 100 mg/mL) .................................................................................... 20
Table 5-1. List of medications that are prohibited due to the potential fo
r drug -drug interaction 
with TAF ................................................................................................................................ 39
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 5 13 June 2019LIST OF IN -TEXT FIGURES
Figure 1-1. Preliminary Mean (SD) GS -6207 Plasma Concentration -Time Profiles Following 
Single -Dose Administration of Subcutaneous Suspension of G S-6207 30 mg, 
100mg, 300 mg and 450mg (N=8 per cohort) ....................................................................... 18
Figure 1-2. Preliminary Mean (SD) GS -6207 Plasma Concentration -Time Profiles Following 
Single -Dose Administration of Oral GS -6207 at 30, 100, 300 and 75 mg 
(N=8 /cohort) ........................................................................................................................... 20
Figure 1-3. Preliminary Mean (SD) GS -6207 Plasma Concentration -Time Profiles Following 
Single -Dose Administration of Sub cutaneous Solutions of GS -6207 at 300 mg 
(N=8/cohort); 300 mg/mL Free Acid and 300 mg/mL Na Salt .............................................. 21
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 6 13 June 2019PROTOCOL SYNOPSIS
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
Study Title : A Phase 1b Randomized, Double- Blinded, Placebo Controlled, 
Multi -Cohort Study  of the Safet y, Pharmacokinetics, and Antiviral 
Activity  of GS -6207 administered subcutaneousl y in HIV -1 Infected 
Subject s
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:136260
Not Applicable
[STUDY_ID_REMOVED]
Study Centers 
Planned:Approximately  15 centers in United States .
Objectives: Part A (Cohorts 1 – 5)
The primary  objective of this study  is as follows:
To evaluate the short- term antiviral activity of GS -6207 compared 
to placebo GS-6207, with respect to the maximum reduction of 
plasma HIV -1 RNA (log 10copies/mL
)from Day 1 through 
Day 10in HIV -1 infected adult subjects who are antiretroviral 
treatment naïve or are experienced but capsid inhibitor (CAI) 
naïve.
The secondary  objectives of this study  are as follows: 
To investigate the safety  and tolerability  of GS -6207 as compared 
to place boGS-6207 in HIV -1 infected subjects .
To characterize the plasma pharmacokinetics (PK) of GS -
6207 in 
HIV-1 infected subjects.
To characterize the PK /pharmacod ynamic srelationship between 
GS-6207 concentration and the viral dy namic sof HIV -1.
To determine the number and percentage of subjects ever 
achieving HIV -1 RNA < 50 copies/mL  by Day  10at each dose 
level .
To examine any  emergence of capsid inhibitor ( CAI)resistance .
GS-6207 and TAF 
Protocol GS-US -200-4072 
Gilead Sciences, Inc. 
Study Design: 
Number of 
Paiiicipants 
Planned: 
Target Population: 
Duration of 
Treatme nt: Part B (C ohort s 6 -8) 
The primaiy objective of this study is as follows: Final 
Amendment4 
• To evaluate the sho1 i-te1 m anti viral activity of TAF with respect 
to the max imum reduction of plasma HIV-1 RNA 
(log10 copies/mL) from Day 1 through Day 10 in HIV-1 infected 
adult subjects who ai·e antiretrovira l treat ment nai:ve or ai·e 
exper ienced but without r esistance to T AF. 
The seconda1y objectives of this study are as follows: 
• To investigate the safety and tolerabi lity of T AF in HIV-1 
infecte d subjects. 
• To character ize the ph aimacok inetics (PK) ofTAF and its 
metabo lites in HIV-1 infec ted subjects. 
• To examine any em ergence of TAF resistance. 
Randomized, double-blin ded, placebo -controlled, multi-coho1 i study 
of GS-6207 (Paii A) and single aim study of TAF (Paii B) 
mon otherapy in subjects with HIV-1 infectio n. 
Approx imately 64 
HIV-1 infected subjects who are antiretrovira l treatme nt nai:ve or 
exper ienced but integrase strand transfe r inhibitor (INST!) nai:ve and 
CAI nai:ve (Paii A only), have not receive d any antiretrov iral therapy 
(ART) within 12 weeks of screening, and ha ve genotypic sensitivity 
to B/F/TAF (sing le tablet regime n of 
bictegrav ir/emtricitabine /tenofovi r alafenamide) 
Single dose (Day 1) 
Diagnosis and Main Subjects with chronic HIV-1 infectio n and meet the following 
Eligibility Criteria: criteria: 
CONFIDENTIAL • Plasma H IV-1 RNA :::: 5,000 copies/mL but :S 400,000 copies /mL 
and CD4+ cell count > 200 cells/mm3 
• Tr eatme nt nai:ve or expe rienced but integrase strand transfer 
inhibitor (INST !) nai:ve and CAI naive (Part A o nly), and have not 
received any ART with in 12 weeks of screening 
Page7 13 June 2019 
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 8 13 June 2019Screening genot ype report must show sensitivity  to B/F/TAF to 
allow TAF monotherap y (Part B) and initiation of B/F/TAF on 
Day 10(Part A and Part B)
Screening genot ype report must show sensitivity  to at least 
oneagent in either non -nucleoside reverse transcriptase inhibitor 
(NNRTI) or protease inhibitor (PI ) class 
to allow its use as part of 
standard of care oral antiretroviral treatment in the future
Have a dequate renal function (estim ated GFR ≥ 70 mL/min)
No clinically  significant abnormalities in ECG at Screening 
Not pregnant or lactating
Willing to initiate B/F/TAF on Day  10 after completion of all 
assessments
Study  Procedures/
Frequency :This study  may  enroll up to 5 cohorts in Pa rt A and up to 3 cohorts in 
Part B, of approximately  8 unique subjects per cohort. All subjects 
will be enrolled a fter the completion of screening procedures and 
following confirmation of study  eligibility . Within each Cohort (n=8)
in Part A , subjects willbe randomized in a 3:1 ratio to receive active 
GS-6207 (n=6) or placebo (n=2) .Within each Cohort (n=8) in Part B, 
subjects will be enrolled to receive active oral TAF .
Part A: A single dose of GS
-6207 or placebo will be administered 
subcutaneousl y (SC) in the abdomen on Day 1. GS -6207 doses may  
be administered as multiple SC injections at different abdominal sites, 
as appropriate. In the case where multiple injections are administered 
for a given dose, the first and last injections should be no more than
30minutes apart. If necessary  for practical reasons, the period may  be 
extended up to 45 minutes.
The Sponsor may  elect to hold dosing, or stop study  enrollment at any  
time based on review of preliminary  safety  and PK data.Cohort Treat ment
1 150 mg GS -6207 or placebo
2 50 mg GS -6207 or placebo
3 450 mg GS -6207 or placebo
4 20 mg GS-6207 or placebo
5 750 mg GS -6207 or placebo
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 9 13 June 2019The doses to be evaluated in Cohorts 2 through 5will be determined 
based on cumulative safety  (through at least Day  14), available PK 
andviral kinetic data from previous cohort sas well as available 
safet y (through at least Day  14) and pharmacokinetic data from 
Study GS-US-
200-4070 (Phase 1, first- in- human, single ascending 
dose study  of GS -6207 SC suspension formulation , in which 
GS-
6207 30 to 450 mg was administered subcutaneously ).As such, 
Cohorts 2-5 may  be initiated in parallel. Selected doses will be either 
lower than, or no more than 3 -fold higher than, previously  evaluated 
doses either in this study  or in Study  GS-US-200- 4070; the same SC 
suspension formulation is being administered in both studies. The 
highest proposed dose in this study ,GS-6207 900 mg, represents a 
2-fold dose escalation over GS -6207 450 mg, which has been shown 
to be safe and well tolerated in Study  GS
-US-200- 4070, based on a 
blinded review of safet y data. 
Observed GS-6207 or placebo ( study  drug )dosing is required at 
Day 1.
Part B: A single dose of TAF will be administe red orally  on Day 1. 
The Sponsor may  elect to hold dosing, or stop study  enrollment at any  
time based on review of preliminary  safety  and PK data.
The doses to be evaluated in Cohorts 7-8will be determined based on 
cumulative safet y (through at least Day  14), available PK and viral 
kinetic data from previous cohort s. Selected doses will be either 
lower than, or no more than 3 -fold higher than, previously  evaluated 
doses in this study .Cohorts 7 and 8 may  be run in parallel.
Observed TAF 
dosing is required at Day 1.
In Part A, following screening and Day
1 visits, subjects will be 
required to visit the clinic on Day s2, 3, 4, 7, 8, 9, 10, 14, 29, 43, 57, 
85, 113, 141, 169, 197 and 225 . 
In Part B, following screening and Day
 1 visits, subjects will be 
required to visit the clinic on Days 2, 3, 4, 5 (if possible ), 6 (if 
possible ), 7, 8, 9, 10, 14, 29, 43, 57, 85, 113, 141, 169, 197 and 225 .Cohort Treatm ent
6 200mg TAF
7 Up to 600 mg TAF
8 Up to 600 mg TAF
GS-6207 and TAF 
Protoco l GS-US -200-4072 
Gilead Sciences , Inc. 
CONFIDENTIAL Final 
Amendment4 
Adverse events, concomitant medicatio ns, complete or 
symp tom-directed physical examinations, and HIV- 1 RNA will be 
perfonned at Scree ning, Day 1, and a ll subsequent study visits. 
CD4+ cell count will be perfonned at Scree ning, Day 1, Day 10, an d 
all subsequent study visits. Other laborato1y analyses (hem atology , 
chemistiy , and urine chemistiy) will be perfonned at Scree ning, 
Days 1, 3, 7, 10, 14, and a ll subsequent study visits. Fasting is 
required for laborato1y analyses at Days 1, 3, 7, 10, 85, 169 and 225. 
ECGs will be perfo1med at Scree ning, Days 1 (pre-dose) , 2, 10, 29, 
57, 85, 169, an d 225. 
A pl asma sample for genotyp ic and phenotyp ic testing of HIV -1 
capsid (Paii A) or HIV- 1 RT (Paii B) wi ll be collected at Scree ning 
an d Day 10 for all subjects to dete1 mine eligibility and to evaluate the 
potential emer gence of resistance agains t GS-6207 (Paii A) or T AF 
(Part B). The screening plasma sample will also be used for genotypic 
testing ofHIV -1 PR, RT, and IN to dete1mine eligib ility. 
A wh ole blood sample for pote ntial HIV DNA genotyping wi ll be 
collected at Days 85, 169 an d 225. 
Subjects who meet the criteda for virolog ic failure after Day 10 will be 
tested for the potentia l deve lopment of resistance against all 
components of the ti·eatine nt regimen, including GS-6207. 
GS-6207 PK sampling (Part A, Cohort s 1 -5 ): 
Blood samples will be collected to dete1mine GS-6207 PK 
(and metabolites , if applicable) in plasma at the following time points 
relative to study diug dosing: 
• D ay 1: 0 (pre-dose) , 1, 2, 4, 8, 12, an d 24 hours post dose. 
• D ays 3, 4, 7, 8, 9, 10, 14, 29, 43, 57, 85, 113, 141, 169, 197 and 
225: a single anytime PK sample will be collec ted. 
TAF PK sampling (Part B, Cohort s 6 -8): 
Plasma PK samples will be collected to deten nine PK of T AF and its 
metabo lite, TFV , at the follow ing time points relative to study diug 
dosing: 
• D ay 1: 0 (pre-dose) , 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 an d 48 hours 
post dose. 
• D ays 4, 5 (if poss ible), 6 (if possible), 7, 8, 9, an d 10 at 
approx imately the same time in the mo rning as pre-dose on 
Day 1. 
Page 10 13 June 2019 
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 11 13 June 2019PBMC PK samples will be collected to determine PKof TFV- DPat 
the following time points relative to study  drug dosing:
Day 1: 0 (pre -dose), 1, 2, 4, 6, 8, 12, 24 and 48 hours post dose.
Days 4, 5 (if possible), 6 (if possible), 7, 8, 9, and 10 at 
approximately  the same time in the morning as pre- dose on 
Day 1.
All subjects will initiate B/F/TAF on Day  10 after completion of all 
assessments .
Test Product, Dose, 
and Mode of 
Administration:Part A:
Study drug will be administered SC in the morning without regard to 
food. Observed study  drug dosing is required .
Cohort 1: GS -6207 150 mg 
Cohort 2: GS -6207 50 mg 
Cohort 3: GS -6207 450 mg
Cohort
4: GS- 6207 20 mg
Cohort
5: GS-6207 750 mg
Part B:
Study drug will be administered orally in the morning under fasted 
conditions. Observed study  drug dosing is required .
Cohort 6: TAF 200 mg
Cohort 7: TAF up to 600 mg
Cohort 8: TAF up to 600 mg
Reference Therapy, 
Dose, and Mode of 
Administration:Part A:
Study drug will be administered SC in the morning without regard to 
food. Observed study  drug dosing is required .
Cohor t 1: Placebo GS-6207 150 mg 
Cohort 2: 
Placebo GS-6207 50 mg 
Cohort 3: Placebo GS -6207 450 mg
Cohort 4: Placebo GS -6207 20 mg
Cohort 5: Placebo GS -6207 750 mg
Part B:
None
Criteria for 
Evaluation:
Safety : Adverse events, vital signs, clinical laboratory  tests, ECG
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 12 13 June 2019Efficacy : Maximum reduction of plasma HIV -1 RNA ( log 10copies/mL )from 
Day 1 through Day  10
Pharmacokinetics: Part A: The following GS -
6207 PK parameters in plasma will be 
calculated: 
AUC 0-t, AUC inf, AUC last,CL/F,t1/2, z, Vz/F, Cmax, Tmax, C last, CD10, 
Tlast
Part B: The following PK parameters will be calculated for TAF and 
TFV in plasma , or TFV- DP in PBMCs, as appropriate :
AUC 0-t, AUC inf, AUC last,CL/F,t1/2, z, Vz/F, Cmax, Tmax, Clast, CD10, 
Tlast
Statistical Methods: Data from the placebo recipients in all Cohorts will be combined to 
form one placebo group for anal ysis purposes. Each GS -6207 
(Part A) and TAF (Part B) dose group will be compared to the 
placebo group in Part A with respect to the efficacy  endpoints. 
Incidence of treatment emergent AEs and graded laboratory  toxicities 
will be summarized by  treatment group.
GS-6207 and TAF (and metabolites, as applicable) PK parameters 
will be summarized by  treatment group using descriptive statistics. 
Part A: A sample siz e of 6 subjects in each GS -
6207 dose group and 
a total of 10 subjects in the placebo group will provide 99% power to 
detect a treatment difference of 2.79 log 10 copies/mL  in maximum 
reduction of HIV -1 RNA between at least one of the GS6207 dose 
groups and the placebo group. In this power anal ysis, it is assumed 
that a common standard deviati on for maximum reduction in HIV-1 
RNA is 0.526 log 10 copies/mL  (based on Study  GS-US- 141- 1219) 
and a 2 -sided t -test is conducted at an alpha level of 0.05.
Part B: A sam ple size of 8subjects in each TAF dose group and a 
total of 1 0subjects in the placebo group will provide 9 9% power to 
detect a treatment difference of 1.43 log 10 copies/mL  in maximum 
reduction of HIV -
1 RNA between at least one of the TAF dose 
groups and the placebo group from Part A . In this power analy sis, it is 
assumed that a common standard deviation for maximum reduction in 
HIV-1 RNA is 0. 52 log 10 copies/mL  (based on Studies
GS-US-
120-0104 and GS -US- 120-1101) and a 2 -sided t -test is 
conducted at an al pha level of 0.05.
This study  will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 13 13 June 2019GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
C degrees Celsius
F degrees Fahrenheit
AE adverse event
AIDS acquired immune deficiency syndrome
ALT alanine aminotransferase
ART antiretroviral therapy
ARV antiretroviral
AST aspartate aminotransferase
AUC area under the plasma/serum/peripheral blood mononuclear cell concentration versus 
time curve
B bictegravir
B/F/TAF bictegravir/emtricitabine/tenofovir alafenamide
BUN blood urea nitrogen
CAI capsid inhibitor
CBC complete blood count
CFR FDA code of federal regulations
CI confidence interval
CK creatine kinase
Clast last measurable plasma concentration
CD10 concentration at Day 10
CL cr creatinine clearance
Cmax the maximum observed serum/plasma/peripheral blood mononuclear (PBMC) 
concentration of drug
Ctau the observed drug concentration at the end of the dosing interval
CPK creatine phosphokinase
CRO contract (or clinical) research organization 
CSR clinical study report
CYP cytochrome P450
DHHS Department of Health and Human Services
DLT Dose -limiting toxicity
DNA deoxyribonucleic acid
DP diphosphate
ECG electrocardiogram
eCRF electronic case report form(s)
eGFR estimated glomerular filtration rate
FAS full analysis set
FDA (United States) Food and Drug Administration
FDC fixed dose combination
FSH follicle stimulating hormone
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 14 13 June 2019FTC emtricitabine
GCP Good Clinical Practice (Guidelines)
GSI, Gilead Gilead Sciences, Inc.
HAART highly active antiretroviral therapy
HBV hepatitis B virus
HBcAb hepatitis B core antibody
HBeAB hepatitis B virus e -antibody
HBsAb hepatitis B surface antibody
HBsAg hepatitis B surface antigen
HCV hepatitis C virus
HIV human immunodeficiency virus
IB Investigator’s Brochure
ICH International Conference on Harmonisation
IDMC Independent Data Monitoring Committee
IEC Independent Ethics Committee
IMP, study drug investigational medicinal products
INSTI integrase strand -transfer inhibitor
INR international normalized ratio
IRB institutional review board
IUD intrauterine device
IWRS interactive web response system
KS Kaposi’s sarcoma
LDL low density lipoprotein
LLT lower level term
LSM least-squares mean
MAD multiple ascending dose
MedDRA Medical Dictionary for Regulatory Activities
Mg milligram
Min minute
mtDNA mitochondrial DNA
NNRTI non-nucleoside reverse transcriptase inhibitor
NRTI nucleoside/nucleotide reverse transcriptase inhibitor
N(t)RTI nucleos(t)ide reverse transcriptase inhibitor
PBMC peripheral blood mononuclear cell
PI protease inhibitor
PK pharmacokinetic
PVE Pham acovigilance and Epidemiology
PXR pregnane X receptor
QD once daily
RNA ribonucleic acid
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 15 13 June 2019RT reverse transcriptase
SAD single ascending dose
SADR serious adverse drug reaction
SAE serious adverse event
SC subcutaneously
SOP standard operating procedures
SUSAR Suspected Unexpected Serious Adverse Reaction
SVR suboptimal virologic rebound
Tmax the maximum time that a drug is present at the maximum concentration in serum
TAF tenofovir alafenamide
TAM thymidine analogue mutations
TDF tenofovir disoproxil fumarate, Viread
TE treatment experienced
TFV tenofovir
Tlast time (observed time point) of C last
ULN upper limit of the normal range
US United States
USPI United States prescribing information
WHO World Health Organization
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 16 13 June 20191. INTRODUCTION
1.1. Background
Human Immunodeficiency  Virus (HIV) -1 infection is a life -threatening and serious disease of 
major public health significance, with approximately  37 million people infected worldwide , and
approximately  15.8 million on antiretroviral (ARV) treatment {Centers for Disease Control 
(CDC) 2017
, UNAIDS 2016 }. Advances in combination antiretr oviral therapy  (ART) for HIV 
have led to significant improvements in morbidity  and mortality  by suppressing viral replication, 
preserving immunologic function, and averting disease progression to acquired 
immunodeficiency  syndrome (AIDS). Standard -
of-care 
for the treatment of HIV -1 infection 
involves the use of a combination of oral ARV drugs (ie, 2 NRTIs plus a third agent) to suppress 
viral replication to below detectable limits, increase CD4 cell counts, and delay  disease 
progression. 
While combination ARV therap y for the treatment of HIV -1 infection is efficacious and well 
tolerated, these agents need to be taken every  day and require near perfect adherence to minimize 
the emergence of drug resistant variants. I n addition, “treatment fatigue” can occur, defined as 
“decreased desire and motivation to maintain vigilance in adhering to a treatment regimen” 
among patients prescribed chronic or life -long treatment {Claborn 2015 }, which can lead to 
nonadherence and treatment failure. As such, there remains a si
gnificant medic al need for ARVs 
that can be administered less frequentl y (ie, long acting drug products), thereby providing an 
alternative treatment option for HIV -1 infected individuals.
The viral capsid (CA) protein play s multiple essential roles in the HIV -1 replicati on cy cle, 
including the assembly  and maturation of new virions, the encapsidation of the viral RNA 
genome and replicative enzy mes into a protective conical capsid shell, the controlled 
disassembly  of the capsid shell following viral entry  to help coordinat e reverse transcription of 
the viral genome, and the active trafficking of viral DNA to the nucleus via a nuclear pore to 
enable formation of an integrated provirus.
1.2. GS-6207
GS-6207 is a novel, first -in-class, selective inhibitor of HIV -1 capsid function, which has potent 
antiviral activity , low human clearance, and phy sicochemical propertie s well suited for 
extended-release parenteral or oral formulations.
1.2.1. General Information
For further information on GS -
6207, please refer to the investigator’s brochure (IB). Information 
in the IB includes:
Nonclinical pharmacology  and toxicology  
Nonclinical pharmacokinetics (PK) and in vitro metabolism
Preclinical pharmacology , pharmacokinetics, and toxicology  
Clinical experience
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 17 13 June 20191.2.2. Additional Clinical Studies
As of January  10, 2019, 3 Phase 1 clinical studies in healthy  volunteers and 1 study  in subjects 
with HIV infection were ongoing:
GS-US-200-4070, a Phase 1 Randomized, Blinded, Placebo - Controlled, Single Ascending Dose
Study  to Evaluate the Safety , Tolerability  and Pharmacokinetics of Subcutaneous GS-6207 
(Aqueous Suspension) in Healthy  Subjects
GS-US-
200-4071, a Phase 1 Study  in Healthy  Volunteers to Evaluate the Safet y, Tolerability 
and Pharmacokinetics of Oral GS -
6207, and the Effect of Food on GS- 6207 Pharmac okinetics
GS-US-200-4538, a Phase 1 Randomized, Blinded, Placebo -Controlled, Single Ascending Dose 
Study  to Evaluate the Safety , Tolerability  and Pharmacokinetics of Subcutaneous GS -
6207 
(Solution Formulations) in Health y Subjects
GS-US-200-4072, a Phase 1 b randomized, double -blinded, placebo -controlled, multi -cohort 
study  of the safet y, pharmacokinetics, and antiviral activity  of GS -6207 administered as a 
subcutaneous injectable suspension in HIV -1 infected subjects.
A brief summary  of the available data f
rom these studies is presented.
1.2.2.1. GS-US-200- 4070 Summary
Study  GS
-US-200- 4070 is an ongoing, Phase 1 study  in healthy  volunteers evaluating the safet y, 
tolerability , and PK of single ascending doses of a GS -6207 subcutaneous suspension. 40 unique 
subjects ac ross 4 dosing cohorts have received either SC GS -6207 or placebo (4:1 ratio). 
Administration of single SC doses of GS
-6207 30 mg (Cohort 1), 100 mg (Cohort 2), 300 mg. 
(Cohort 3) and 450 mg (Cohort 4) is complete. PK sampling for Cohorts 1 and 2 (through 
Day169 [24 weeks] post dose) is complete and ongoing for Cohorts 3 and 4 (through Day 225 
[32 weeks] post dose). Preliminary  PK profiles and PK parameters of subcutaneous GS -6207 
administered as single doses of 30 mg, 100 mg, 300 mg and 450 mg are presente d in Figure 1-1
and Table 1-1below. Preliminary  PK data are available for 168 day s post dose for Cohorts 1, 2 
and 4, and through 196 days post -dose for Cohort 3. 
GS-6207 PK profiles ( Table 1-1) are consistent with sustained delivery . The PK is characterized 
by 
prolonged exposure, with measureable concentrations for up to 196 days [28 weeks], to date. 
The median apparent terminal t 1/2 is 30- 43 day s. Increases in GS- 6207 mean C maxand AUC infare 
approximately  dose proportional over the dose range of 30
-450 mg.
In a preliminary  blinded review of the available safety  data through February  1, 2019 (n=40), no 
deaths, serious adverse events ( SAEs), or Grade 3 -4 adverse events (AEs) have been reported. 
Injection site reactions occurred in 21 of 40 subjects (53%) these included injection site ery thema 
(15 subjects, 38%), injection site pain (14 subjects, 35%), injection site nodules (9 subjects,
23%), injection site induration (8 subjects, 20%), and injection site swelling (7 subjects, 18%). 
The only  other AE that was reported b y more than 10% of subjects was headache (5/40, 13%).
GS-6207 and TAF 
Protocol GS-US -200-4072 Final 
Gilead Sciences , Inc. Amendmen t 4 
Figu re 1-1. Prelimin ary Mean (SD) GS-6207 Plasma Concentration -Time Proflles 
Following Single-Dose Admini stration of Subcutan eous Suspension of 
GS-6207 30 m g, 100 mg, 300 mg a nd 450mg (N=8 per c ohort ) 
-...I 
E -Cl) 
C: -,-.. 
0 N 
<9 (/) 
(!) 100 
10 
1 ....,. Cohort 1 : 30 mg 
....,. Cohort 2: 100 mg 
-+ Coho rt 3: 300 mg 
.. Cohort 4: 450 mg 
0.1+- ...... -............ -...... -----------.-----.,-----
0 14 28 42 56 70 84 98 112 126 140 154 168 182 196 
Time , day 
Table 1-1. Study GS-US-2 00-4070 Prelimin ary Plasma Pharmacokin etic 
Paramet ers of GS-6207 Following Single Dose Admini stration of 
Subcutaneou s Suspens ion of GS-62 07, 30-450 mg 
Coho1 1 l Cohort 2 Cohor t 3 
N=8 N=8 N=8 
Dose (Injecti on Volume) 30 mg (1 X 0.3 l00mg(lxlmL ) 300 mg (3 x 1 mL) mL) 
PK Param eter 
Mea n(%CV) 
AUCinf (hr*ng/mL) 7740 (8.75)" 27600 (40.4)h 86300 (18.5)c 
AUC1as1 (hr*ng/mL) 6800 (13.1) 25900 (44.6) 81300 (1 8.0) 
AUC %Ex trapolated(%) 12.3 (36.3) 6.92 (70.5) 5.45 (113) 
Cmax (ng/mL) 3.24 (39.8) 14.7 (58.4) 47.9 (27.7) 
Cmo(ng/mL) 2.28 (36.7) 10.7 (57.7) 31.4 (35.2) 
tmax ( day) t 35.0 (22.3, 36.8) 21.0 (11.8, 36.8) 31.5 (17.5, 35.0) 
t112(day)t 35.5 (31.5, 40.2)" 30.3 (23.6, 48.2)h 43.1 ( 26.5, 46.5)° 
Pha1macokine tic parameters are presented as Mean (%CV) , and shown to 3 significan t digits 
fMedian (Ql,Q3); •n=4 ; bn=6 ; c n=7; ND= Not yet dete1mined 
CONFIDENTIAL Page 18 Cohor t 4 
N=8 
450 mg (3 X 1.5 mL) 
111000 (25. 7)° 
102000 (21.0) 
6.79 (68.4) 
58.4 (22.9) 
47.1 ( 44.7) 
14.0 (6.50, 29.8) 
39.9 (32.8, 48.8)° 
13 June 2019 
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 19 13 June 20191.2.2.2. GS-US-200- 4071 Summary
Study  GS
-US-200- 4071 is an ongoing, Phase 1 study  in healthy  volunteers evaluating the safet y,
tolerability , and PK of single and multiple ascending doses of a GS -6207 oral capsule. As of 
January  10, 2019, a total of 40 unique subjects have received GS -6207 in Cohorts 1 - 4.
In Cohorts 1 and 2, each subject was randomized to receive either GS -6207 (N=8; 50 mg/mL) or 
matching placebo (N=2); a single dose was administered under fasted conditions on Day 1 
followed b y a 10 -day washout period, then 10 days of once- daily  doses on Day s 11-20.
Preliminary single dose PK profiles from Cohorts 1 and 2 ( Figure 1-2) suggest ed that the 10 day 
washout period was not sufficient to allow for characterization
 of the elimination phase 
following a single oral dose of GS -6207. As a result, the protocol was amended to limit 
evaluation of GS -6207 PK to single ascending doses with exte nded PK sampling to allow for 
characterization of the single dose oral PK prior to any  further multiple dosing.
A summary  of the preliminary  PK parameters of oral GS -6207 after administration of single and 
multiple doses of 30 mg (50 mg/mL; Cohort 1) and 1 00 mg (50 mg/mL
; Cohort 2) are presented 
in Table 1-2below. Maximum plasma concentrations of GS -6207 (C max) occurred between 3.5 
and 29 hours (median T max). Following multiple dosing, the mean C maxand AUC 0-24 were at least 
10-fold higher than those after a single dose.
Table 1-2. Study GS -US-200- 4071 Preliminary Plasma Pharmacokinetic 
Parameters of GS -6207 Following Single and Multiple Dose Oral 
Administration of 30 mg 
(50mg/mL) and 100 mg (50mg/mL)
Cohort 1 (N=8) Cohort 2 (N=8)
30 mg SD 30 mg MD 100 mg SD 100 mg MD
Cmax (ng/mL) 1.16 (23.9) 12.2 (17.1) 2.70 (55.4) 41.3 (53.8)
tmax (hr)†29.0 (4.00, 90.0) 3.50 (1.89, 10.0) 26.0 (4.00, 96.0) 4.00 (4.00, 10.5)
AUC 0-24hr (hr*ng/mL) 17.6 (19.7) 232 (17.9) 34.8 (47.3) 843 (56.5)
AUC last (hr*ng/mL) 147 (29.0) - 319 (46.0) -
Pharmacokinetic parameters are presented as Mean (%CV), and shown to 3 significant digits
AUC 0-24hr= AUC from time zero through 24 hours post dose; AUC last = AUC from time zero to Day 7 post dose for single dose
†Median (Q1,Q3)
In Cohorts 3 and 4, each subject was randomized to receive a single dose of either GS -
6207 
(N=8; 100 mg/mL ) or matching placebo (N=2).
PK profiles and preliminary  PK parameters of GS- 6207 after administration of single oral doses 
of 300 mg (100 mg/mL; Cohort 3) and 75 mg (100 mg/mL ; Cohort 4) are presented in Figure 1-2
and Table 1-3below. Maximum plasma concentrations of GS -6207 (C max) occurred between 
6.00 and 38 hours (median T max). The increase in C max was less than dose proportional between 
75 and 300 mg. Based on the available PK from Cohort 3, the estimated terminal t 1/2 of GS -
6207 
is approximately  16 day s.
GS-6207 and TAF 
Protocol GS-US -200-4072 Final 
Gilead Sciences , Inc. Amendment 4 
Figu re 1-2. Prelimina ry Mea n (SD) GS-6207 Plasma Concentration -Time Proflles 
Following Single-Dose Admini stration of Oral GS-6207 at 30, 100, 300 
and 75 mg (N=8/cohort ) 
10 .....,_ Cohort 1, 30 mg (50 mg/ml) 
_....,_ Coho rt 2, 100 mg (50 mg/ml) 
...J ...... Coho rt 3, 300 mg (1 00 mg/ml) E 
O> ---Coho rt 4, 75 mg (100 mg/ml ) C 
,-..-
0 1 
<'I <!) 
U) 
C) 
0.1 .... ----------------
0 7 
Table 1-3. 
Parameter 
Cmax (ng/mL) 
tmax (hr) t 
AUC1as1 (hr*ng/mL) 
AUCw (hr*ng/mL ) 
AUC %Extrapolated (%) 
t112t(days) 14 21 28 35 
Time, day 
Study GS-US-2 00-4071 Prelimin ary Plasma Pharmacokin etic 
Paramet ers of GS-6207 Following Single Dose Oral Admini stration in 
Cohort s 3 (300 mg, 10 mg/mL) and 4 (7 mg, 100 mg/mL) 
Coho1 1 3 (N=S) Cohor t 4 (N=S) 
300 mg SD 75 mg SD 
2.33 (31.9) 1.33 (41.7) 
6.00 (4.00, 16.5) 38.0 (4.00-72.0) 
877 ( 46.4) 217 (56.3) 
1200 (29.1) TBD• 
29.3 (39.9) 52.9 (20.7) 
15.7 (11.1, 17.5) TBD• 
Pha1macokinetic parameter s are presented as Mean (%CV), and shown to 3 significant digits; TBD = to be dete1mined , fMedian 
(Ql,Q3); • AUC % extrapolated is currently too large to provide estimates of AUCini and ti12, param eters will be calculated upon 
availability of data 
In a prelimimuy blind ed review of safety data to date as of Januar y 10, 2019 of Cohoits 1-4, 
no de aths, serious ad verse even ts (SAEs), or G rade 2-4 adverse events (AEs) have been repo 1ted; 
no AE h as been repo1ted in more than 1 subj ect. 
CONF IDENTIAL Page 20 13 June 2019 
GS-6207 and TAF 
Protocol GS-US -200-4072 
Gilead Sciences , Inc. 
1.2.2.3. GS-US-200-4538 Summ aiy Final 
Amendment4 
Study GS-US-200-4538 is an ongo ing, Phase 1 study in healthy volunteers evaluating the safety , 
tolerability , and PK of single ascending doses of GS-6207 subcuta neous solution fo1 mulations. 
40 unique su bjects across 4 dosing cohorts have received either SC GS-6207 or placebo 
(4:1 ratio). Single SC doses of three fo1 m ulatio ns (300 mg/mL free acid; Coho1i 1,300 mg/mL 
Na salt; Coho1i 5, and 1 50 mg/mL Na salt; Coho1 i 9) of GS-6207 have been admini stered at a 
300 mg dose. Coho1 i 6 h as received a 900 mg dose of 300 mg/mL Na salt. PK samples will be 
collec ted for up to 450 days. PK anal ysis is on going. 
Prelimin aiy PK p rofiles of GS-6207 after admini stratio n of s ingle 300 mg SC doses of 
300 mg/mL free acid (Coho1 i 1) and 300 mg/mL Na salt (Coho1i 5) are prese nted in Figure 1-3 
below. To date, there is insufficient data to calcu late PK pai·ameters from t hese solution 
fo1m ulations. Plasma concentratio ns of GS-6207 over the first 42 days were at least 5 fold lower 
than t hose following a 300 mg dose of the GS-6207 SC suspen sion evaluated in Study 
GS-US-200-4070 (Figure 1-1 ). 
In a preliminaiy blinded review of safety data as of Januaiy 10, 2019 (n=20) no deaths, serio us 
adve rse events (SAEs) , or Grade 3-4 adverse events (AEs) have been repor ted. Prelimin aiy 
info1matio n provided by the investigato r after 14 days of follow up indicates a favorab le safety 
profile in subjects who received a 900 mg dose of GS-6207 in Coho1i 6. 
Figure 1-3. 
100 
...J 
-E 10 
0) 
C 
" 0 N co 
J, 1 
0 Preliminary Mean (SD) GS-620 7 Plasma Concentration-Time Proflles 
Following Single-Do se Admini stration of Subcutaneou s Solution s of 
GS-620 7 at 300 mg (N=8/cohort ); 300 mg/mL Free Acid and 
300 mg/mL Na S alt 
• Coho rt 1; 300 mg (300m g/ml Free Acid) 
Coho rt 5; 300 mg (300mg/ml Na salt) 
0.1---------------
0 7 
CONFIDENTIAL 14 21 
Time, day 28 35 42 
Page 21 13 June 2019 
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 22 13 June 20191.2.2.4. GS-US-200- 4072 Summary
Study  GS
-US-200- 4072 is an ongoing, Phase 1b randomized, double - blinded, 
placebo- controlled, multi -cohort stud y of the safety, pharmacokinetics, and antiviral activity  of 
GS-6207 administered as a subcutaneous injectable suspension in HIV- 1 infected subjects 
conducted under IND 136260 (injectable). The primary  objective of this study  is to evaluate the 
short -term antiviral activity  of GS -6207 compared to placebo GS -6207, with respect to the 
maximum reduction of plasma HIV -1 RNA (log 10 copies/mL ) from Day  1 through Day 10 in 
HIV-1 infected adult subjects who are antiretroviral treatment naïve or are treatment-experienced 
but not currentl y taking ARV tre atment. This study  may enroll up to 40subjects across 5 cohorts 
of 8 unique subjects per cohort. 
All subjects will receive Biktarv y as a standard -of-care oral combination antiretroviral therapy  
immediately  after completing the assessment of the primary  endpoint (ie, Day 10) in order to 
minimize the risk of exposing subjects to GS -6207 monotherapy  for an extended period of time. 
This study  is currently  enrolling.
In a preliminary  blinded review of the available safety  data as of February  26, 2019 when the 
first cohort had all completed Day  10of GS -6207 150 mg , no deaths, serious adverse events 
(SAEs), or Grade 2-4 adverse events (AEs) have been reported . The preliminary  safet y data 
indicate a favorable safety profile in subjects with HIV -1 infection. Preliminary  blinded HIV -
1
RNA data showed a mean (range) 1.76 (1.49 -2.06) log10 copies/mL  decline in HIV -1RNA at 
Day 10.
1.3. Tenofovir alafenamide ( TAF )
Following its release from the prodrug TAF, TFV is metabolized intracellularly  to the active 
metabolite, tenofovir diphosphate (TFV -DP), a competitive inhibitor of HIV - 1 reverse 
transcriptase that terminates the elongation of the viral DNA chain during the process of 
retroviral replication.
1.3.1. General Information
For further information on TAF, please refer to th
e investigator’s brochure (IB). Information in 
the IB includes:
Nonclinical pharmacology  and toxicology  
Nonclinical pharmacokinetics (PK) and in vitro metabolism
Preclinical pharmacology , pharmacokinetics, and toxicology
Clinical experience
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 23 13 June 20191.4. Rationale for t his Study
Current oral combination ARV therap y can achieve and maintain virologic suppression in the 
majority  of patients and even provide second or third line regimens after they  fail the ir first line 
regimen for efficacy  or safet y reasons . However ,there still remains a significant unmet medical 
need for heavil y treatment experienced (TE) HIV patients, which can be met with an 
antiretroviral agent with a new mechanism of action. As there is no cross -resistance with agents 
in existing classes, such a gents can be used in patients who develop resistance to agents in 
existing classes or in virologicall y suppressed patients without concern for losing certain classes 
altogether even if they  develop resistance. 
While current oral combination ARV t herap y for the treatment of HIV -1 infection is efficacious 
and generally  well tolerated, these agents need to be taken every  day and require near -perfect
adherence to achieve and maintain virologic suppression and minimize the emergence of 
drug-resistant variants. Given the potency  of contemporary  ART, a detectable viral load 
identified during chronic care for a patient with stable access to ART is most likely  the result of 
poor adherence {The Department of Health and Human Services (DHHS) Panel on 
Antiretroviral Guidelines for Adults and Adolescents 2017 }.As such, there remains a significant 
medical need for ARVs that can be adm inistered less frequently  (i
.e., long -acting drug products )
for all patients
. 
1.4.1. Rationale for the development of GS -6207
GS-6207 is a selective, multi -stage inhibitor of HIV -1 capsid function being develop edas a 
novel therapeutic for the treatment of HIV -1infection . GS-6207 is characterized by  potent 
antiviral activity , a novel resistance profile, low predicted human clearance, low potential for 
drug-drug interactions, and low aqueous solubility .GS-6207 is anticipated to be active against 
all major ty pes of HIV -1, including those that have developed resistance to existing classes of 
ARVs (eg, 
nucleoside reverse transcriptase inhibitors [NRTI s], nonnucleoside reverse 
transcriptase inhibitors [NNRTI s],protease inhibitors [PI s], and integrase strand- transfer
inhibitors [I NSTIs]). This makes GS -6207 a useful antiretroviral agent for heavily  treatment 
experienced patients with few options due to multiclass resistant HIV -1 infection. I n addition, 
the physicochemical characteristics allow GS
-6207 to be well suite d for an extended- release
parenteral formulation that can potentiall y be used as a novel long -acting antiretroviral 
(ARV )
treatment administered monthly  or less frequentl y. 
To date, Gilead evaluated GS -6207 only  in healthy  volunteers and has not observed any safety 
signal of concern (see S ection 1.2.2). The current study  (GS-US- 200-4072) is the first study  of 
GS-6207 in humans with HIV -1 infection. This study  will assess the safet y, tolerability , PK, and 
antiviral activity  of GS -6207 in treatment naïve or experienced but capsid inhibitor (CAI) and 
integrase strand transfer inhibitor (INSTI) naive . The study  involves 1 0days of monotherap y that 
will allow for the ass essment of a ntiviral activity  over a range of GS-6207 exposures in HI V-1 
infected subjects. The study  will also allow for the evalua tion of the safet y and PK of GS -6207 in 
HIV-1 infected subjects . The data from this study  will support dose selection for Phase 2 and 
3studies.
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 24 13 June 20191.4.2. Rational e for the d evelopment of weekly oral TAF
TAF is a next generation oral prodrug of TFV that, compared to TDF, delivers increased 
intracellular levels of TFV -DP, in conjunction with lower s ystemic TFV exposure. TAF provides 
enhanced delivery  of TFV to peripheral blood mononuclear cells (PBMCs), ly mphatic organs, 
and hepatocy tes, resulting in higher intracellular levels of the active phosphory lated moiety  
TFV -DP, more effective suppression of residual viral replication in a wider range of reservoir 
and anatomic sanctuaries of HIV, and lower s ystemic circulating levels of TFV, resulting in a 
better overall profile. 
The combination of low circulating TFV and high intracellular TFV -DP (as compared with TDF) 
raises the prospect that less frequent administration of higher dose TAF may  be a safe and 
effective alternative for patients for whom daily adherence is challenging .
While current oral combination ARV t herap y for the treatment of HIV -1 infection is efficacious 
and generally  well tolerated, these agents need to be taken every  day and require near -perfect
adherence to achieve and maintain virologic suppression and minimize the emergence of 
drug-resistant variants. Given the potency  of contemporary  ART, a detectable viral load 
identi fied during chronic care for a patient with stable access to ART is most likely  the result of 
poor adherence {The Department of Health and Human Services (DHHS) Panel on 
Antiretroviral Guidelines for Adults and Adolescents 2017 }.As such, there remains a significant 
medical need for ARVs that can be administered less frequently  (i
.e., long -acting drug products )
forall patients. An oral ARV which could be administered weekl y might offer the potential for 
improved treatment for some patients . If so, viral suppression for 10 day safter a single dose can 
support a weekl yadministration
. 
1.5. Rationale for the Dose Selection
1.5.1. GS-6207
Selection of the GS -6207 SC suspension doses for this study  takes into consideration the 
available safet y, tolerability  and PK data for SC GS -6207 from the ongoing SC single ascending 
dose study  in heal thy volunteers (GS- US-200-4070), as well as preliminary safet y and antiviral 
activity  data in this study following administration of GS- 6207 150 mg to HIV -1 infected 
subjects (GS-US-200- 4072) .
As of February  1, 2019, 40 subjects (32 active and 8 placebo) have received a single dose of 
GS-
6207 via subcut aneous injection (SC 30 to 450 mg). All subje cts have completed at least 
168days of follow up or discontinued the study . In the blinded review of safet y data, GS-6207 
was generall y well -tolerated. T here have been no deaths, serious adverse events (SAEs), or 
Grade 3 -4 adverse events (AEs) reported. Injection site reactions occurred in 21 of 40 subjects 
(53%) these included injection site ery thema (15 subjects, 38%), injection site pain (14 subjects, 
35%), injection site nodules (9 subjects, 23%), injection site induration (8 subjects, 20%), and 
injection site swelling (7 subjects, 18%). The onl y other AE that was reported by  more than 10% 
of subjects was headache (5/40, 13%).
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 25 13 June 2019GS-6207 PK was shown to be dose proportional across the dose range of 30 to 450 mg in Study  
GS-US-200-4070. Based on the PK data from Study  GS-US- 200-4070, GS -6207 150 mg is 
expected to result in a GS -6207 concentration at Day  10 (C t) that is 4 -fold higher than the protein 
adjusted EC 95against wild ty pe HIV virus (paEC 95; 3.8 ng/mL) , and was selected for evaluation 
in Cohort 1 (Table 1-1) of this study .PK anal ysis is ongoing. Preliminary  blinded data from 
Cohort 1 demonstrated a favorable safety  profile an d a mean decrease of 1.76 log10 copies/mL 
in HIV -1 RNA at Day  10 followin g administration of 150 mg GS -
6207. Based on these data, a 
dose of 50 mg and 450 mg have been selected for Cohorts 2 and 3, respectively . Doses of 20 mg 
and 750 mg were subsequently
 selected for Cohorts 4 and 5 respectively .
1.5.2. TAF
The PK, safet y and efficacy of TAF have been comprehensivel y characterized across several 
TAF -containing clinical development programs including in combination with B /F/TAF used in 
this study . The results of clinical studies, including the proof -of-concept TAF monotherapy  
evaluation in HIV -infected subjects, informed selection of TAF oral doses for this study .
Briefl y, Phase 1 studies demonstrated a favorable safet y profile and approximately dose 
proportional increases in exposure for TAF, TFV and TFV -DP (active intracellular metabolite) 
across the dose range of 8 to 125 mg. In Phase 3 clinical studies, TAF 25 mg exhibited a 
favorable safety  profile when dosed in subjects with chronic hepatitis B infection (CHB) or in 
combination with other ARV agents for the treatment of HIV.
The res ults from the two TAF proof -of-concept short -term (10- 14 day ) monotherapy  studies in 
treatment -naïve HIV -1 subjects showed dose -dependent mean reductions in HIV -1 RNA of 0.99, 
1.43, 1.52 log 10 copies/mL on Day  10 at TAF doses of 8 mg, 25 mg, 40 mg QD, respectivel y, and 
a mean decrease of 1.48 log 10 copies/mL on Day  10at TAF 120 mg QD (GS-US- 120-0104 and 
GS-US-
120-1101) {Ruane 2013}. Based on these data, a single dose of TAF 200 mg was chosen 
for the initial evaluation in this study  (Part B, Cohort 6). Assuming dose proportionality , TAF 
200 mg is predicted to provide intracellular exposure of the ac tivemetabolite, TFV -DP, at 
Day 10 similar to that observed following dail y dosing of 25 mg TAF ; and as such achieve 
comparable viral load reduction through Day 10.
TAF d oses to be evaluated in 
adaptive c ohorts 7 and 8 (up to 600 mg single dose ) will be 
select ed based on cumulative safet y, antiviral activity and available pharmacokinetic data from 
previous cohorts in Part B. These doses will be either lower than, or no more than 3- fold higher 
than, previously  evaluated doses. Following a dministration of 600 mg TAF, predicted TFV C max
(236 ng/mL) is projected to be similar to predicted average dail y TFV exposures (1033 ng/mL) 
and up to 50% lower , respectivel y,than that observed following daily  administration of TDF 
300mg (Cmax: 300 ng/m L and average daily  exposure : 2290 ng/mL ); accordingl y,doses of up to 
600mg TAF 
are supported by  clinical safet y data from the TDF 300 mg development program 
{STRI BILD® 2019 , VIREAD 2019}.
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 26 13 June 2019The proposed dose range allows for sufficient dose-separation between cohorts for examining 
safet y, antiviral activity and pharmacokinetics of a single dose of oral TAF , and maximizes the 
probability  of observing a dose /exposure -response relationship. Since there are sufficient 
subjects in the placebo group from Part A, and the safet y of TAF >125 mg is unknown
, all 
subjects in Part B will be enrolled to receive TAF.
1.6. Risk/Benefit Assessment for the Study
Potential risks associated with the study include unknown adverse events (AEs), including 
injection site reaction, general risks associated with frequent clinic visits and laboratory  blood 
draws, and the associated pain and discomfort of multiple phlebotomies. Strategies to mitigate 
these risks include close monitoring of lab values as well as AEs. Parameters for monitoring of
AEs will be well defined and closel yfollowed.
In addition, potential risks to HIV positive subject sinclude prolonged exposure (weeks to 
months) to subtherapeutic concentra tions of GS-6207, which can lead to HIV- 1 developing 
resistance to GS-6207. Strategies to mitigate these risks include initiation of B/F/TAF , which is 
an FDA -approved single tablet regimen with established efficacy  and safet y profile , on Day 10. 
With the initiation of B/F/TAF most subjects are expected to achieve virologic suppression 
within a few weeks, which substantially  reduces the risk of HIV -1 developing resistance.
Similarly , subjects receiving TAF monotherapy  have a risk of developing TA F resistance. 
However, TAF has a shorter half -life than GS -6207 and the same mitigation strateg y ofinitiation 
of B/F/TAF at Day  10 will be used.
There is no direct benefit to subjects participating in this study
; however, data from this study
will support the development of GS -6207 and weekly  TAF for the treatment of HIV -1 infection. 
Potential benefits may include the participant’s contribution to understanding the antiviral 
activity , safety, tolerability ,and pharmacokinetics of GS -6207 (Part A) or TAF (P art B)
(i.e.how much GS -6207 or TAF gets into the blood stream) .
Given the above, the benefit -risk balance for this study  is considered positive.
1.7. Compliance
This study  will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory  requirements.
GS-6207 and TAF 
Protoco l GS-US-200-4072 
Gilead Sciences , Inc. 
2. OBJECTIVES 
Part A (Cohorts 1 -5) 
The prima1y object ive of this study is as follows: Final 
Amendment4 
• To evaluate the sho1t-te1m antiviral activity of GS-6207 compared to placebo GS-6207 , with 
respect to the maximum reduction of plasma HIV-I RNA (log1 0 copies /mL) from Day 1 
throu gh Day 10 in HIV- I infected adult subjects who are antiretroviral treatment na'ive or are 
expe rienced but capsid inhibitor (CAI) na'ive. 
The secondaiy objectives of this study ai·e as follows: 
• To investigate the safety and tolerability of GS-6207 as compai·ed to placebo GS-6207 in 
HIV-I infected subjects 
• To chai·acte rize the plasma phannacokinetics (PK) of GS-6207 in HIV- I infected subjects 
• To chai·acte rize the PK/phaimacodynamics of GS-6207 concentration and viral dynamics of 
HIV-I. 
• To dete1min e the number and percentage of subjects ever achieving HIV- I RNA 
< 50 copies/mL by Day 10 at each dose level 
• To exainine any emergence of caps id inhibitor (CAI) resistance 
Part B (Cohorts 6 -8) 
The prima1y objective of this study is as follows: 
• To evaluate the sho1t -tenn antiviral activity ofTAF with respect to the maximum reduction 
of plasma HIV-I RNA (log1 0 copies /mL) from Day 1 through D ay 10 in HIV-I infected adult 
subjects who ai·e antiretroviral treatment na'ive or ai·e experie nced but without resistance to 
TAF. 
The secondaiy objectives of this study ai·e as follows: 
• To investigate the safety and tolerability of T AF in HIV- I infected subjects 
• To chai·acte rize the phannacokinetics (PK) ofTAF and its metabolites in HIV-I infected 
subjects 
• To exainine any emergence of T AF resistance . 
I 
CONFIDENTIAL Page 27 13 June 2019 
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 28 13 June 20193. STUDY  DESIGN
3.1. Endpoints
The primary  endpoint is the maximum reduction of plasma HIV -1 RNA (log 10copies/mL ) from 
Day 1 through Day  10.
Secondary
 endpoints include: 
Incidences of adverse events and graded laboratory  abnormalities
PK parameters of GS-6207 (Part A) and TAF (and its metabolites, as appro priate) (Part B)
Correlation between Ct(concentration at Day  10) of GS - 6207 (Part A) and the maximum 
reduction of plasma HIV -1 RNA ( log 10copies/mL) from Day 1 through Day  10 
Number and percentage of subjects ever achieving HIV-1 RNA < 50copies/mL  by Day 10
(Part A)
Incidences of 
any emergence of CAI  resistance (Part A)
Incidences of an y emergence of TAF resistance (Part B)
3.2. Study Design
Randomized, double -blinded, placebo -controlled, multi- cohort study  of GS -6207 (Part A) and 
single -arm study  of TAF (Part B) monotherapy  in subjects with HIV -1 infection
3.3. Study Treatments
This study  may  enroll up to 5cohorts in Part A and up to 3 cohorts in Part B, of approximately  
8unique subjects per cohort. All subjects will be enrolled a fter the completion of screening 
procedures and following confirmation of stud y eligibility . Within each Cohort (n=8) in PartA , 
subjects will be randomized in a 3:1 ratio to receive active GS -6207 (n=6) or placebo (n=2) .
Within each Cohort (n=8) in Part B , subjects will be enrolled to receive active oral TAF .
Part A: A single dose of GS
-6207 or placebo will be administered subcutaneously (SC) in the 
abdomen on Day  1. GS -6207 doses may  be administered as m ultiple SC injections at different 
abdominal sites, as appropriate. In the case where multiple injections are administered for a 
given dose, the first and last injections should be no more than 30minutes apart. If necessary  for 
practical reasons, the peri od may  be extended up to 45 minutes. 
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 29 13 June 2019Cohort Treat ment
1 150 mg GS -6207
2 50 mg GS -6207
3 450 mg GS -6207
4 20mg GS -6207
5 750mg GS -6207
The Sponsor may  elect to hold dosing, or stop study  enrollment at any  time based on review of 
preliminary  safety  and PK data.
The doses to be evaluated in Cohorts 2 through 5will be determined based on cumulative safet y 
(through at least Day  14),availabl e PK and viral kinetic data from previous c ohort sas well as
available safet y (through at least Day  14) and pharmacokinetic data from Study 
GS-US-200-4070 (Phase 1, first- in-human, single ascending dose study  of GS -6207 SC 
suspension formulation). Cohorts 
2-5 may  be initiated in parallel. Selected doses will be either 
lower than, or no more than 3 -fold higher than, previously  evaluated doses either in this study  or 
in Study  GS-US-200- 4070; the same SC suspension formulation is being administered in both 
studies. The highest proposed dose in this study , GS-6207 900 mg, represents a 2 -fold dose 
escalation over GS -6207 450 mg, which has been shown to be s afe and well tolerated in 
Study GS-US-
200-4070, based on a blinded review of safety  data. 
Observed stud y drug dosing is required at Day 1.
Part B: A single dose of TAF will be administered orally  on Day 1.
The Sponsor may  elect to hold dosing, or stop study  enrollment at any  time based on review of 
preliminary  safety  and PK data.
The doses to be evaluated in Cohorts 7 -8will be determined based on cumulative safet y 
(through at least Day  14), available PK and viral kinetic data from previous cohort s. Selected 
doses will be either lower than, or no more than 3 -fold higher than, previously  evaluated doses in 
this study . Cohorts 7 and 8 may  be run in parallel.
Observed TAF dosing is required at Day 1.Cohort Treatm ent
6 200 mg TAF
7 Up to 600 mg TAF
8 Up to 600 mg TAF
GS-6207 and TAF 
Protoco l GS-US -200-4072 
Gilead Sciences , Inc. 
3.4. Duration of Treatment Final 
Amendment4 
Regardless of Coho1 t in this study, the proced mes are identical. Following screening and D ay 1 
visits, subjects will be re quired to visit the clinic on Days 2, 3, 4, 5 (Pait B only, if possible) , 
6 (Pait B on ly, if possible), 7, 8, 9, 10, 14, 29, 43, 57, 85, 113, 141, 169, 197 and 225. 
All subjects will be dosed with either active GS-6207 or placebo (Pait A) or TAF (Pait B) on 
Day 1. 
-
-
CONFIDENTIAL Page 30 13 June 2019 
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 31 13 June 20194. SUBJECT POPULA TION
4.1. Number of Subjects and Subject Selection
Approximately 64subjects who meet all the eligibility  criteria will be enrolled. 
Replacement subjects may be enrolled for subjects who do not complete all procedures for 
reasons other than discontinuation due to monotherapy  treatment related adverse events.
4.2. Inclusion Criteria (Part s Aand B)
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study.
1)The ability  to understand and sign a written informed consent form, which must be obtained 
prior t oinitiation of study procedures
2)Must be between 18 and 65 years of age, inclusive on the date of the screening visit
3)Cohorts 1 - 5: Antiretroviral trea tment naïve OR experienced but capsid inhibitor (CAI) and 
integrase strand transfer inhibitor (INSTI) naïve and have not received any anti -HIV 
treatment, including antiretroviral medications received for prevention (PrEP) or post 
exposure prophy laxis (PEP) , within 12 weeks prior to screening
Cohorts 6 
- 8:Antiretroviral treatment naïve OR experienced but integrase strand transfer 
inhibitor (I NSTI) naïve and have not received any anti -HIV treatment, including 
antiretroviral medications received for prevention (PrEP) or post exposure prophy laxis 
(PEP), within 12 weeks prior to screening
4)Plasma 
HIV-1 RNA ≥ 5,000 copies/mL  but <400,000 copies /mL 
5)CD4+ cell count > 200 cells/mm3
6)Cohorts 1 - 5: Screening HIV-1 capsid genot ypic report provided b y Gilead must not show 
any mutation known to be associated with in vitro resistance to GS- 6207 (L56I, M66I, 
Q67H, Q67Y, K70N, N74D, N74S, A105E, or T107N in HIV- 1 capsid)
Cohorts 6 - 8: HIV-1 capsid genot yping criteria do not apply
7) Must be willing to initiate B/F/ TAF on Day  10
8)Screening genot ype report provided b y Gilead must show genot ypic sensitivity  to the 
components of 
B/F/TAF atScreening to allow its initiation on Day  10
9)
No documented or suspected resistance to the components of B/F/TAF to allow its initiation 
on Day  10
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 32 13 June 201910) S creening genot ype report provided b y Gilead must show genot ypic sensitivity  to at least 
oneagent in the non -nucleoside reverse transcriptase inhibitor (NNRTI), or protease inhibitor 
(PI) class essuch that a viable standa rd-of-care ARV regimen can be constructed inthe future
11)Normal ECG (if abnormal, determined b y the Investigator to be not clinically  significant)
12)Adequate renal function:
Estimated glomerular filtration rate 70mL/min according to the Cockcroft -Gault for mula
{Cockcroft 1976 }:
Male: (140 –age in years) (wt in kg) CLcr (mL /min)
72(serum creatinine in mg/dL)
Female: (140 –age in years) (wt in kg) 0.85  CLcr (mL/min)
72(serum creatinine in mg/dL)
13)Hepatic transaminases (AST and ALT) 5upper limit of normal (ULN )
14)Alkaline phosphatase ≤ULN
15)Total bilirubin 1.5mg/d L, or normal direct bilirubin
16)Adequate hematologic function (absolute neutrophil count 750/mm3; platelets 
50,000/mm3; hemoglobin 8.5
g/dL) (Those with chronic neutropenia with no clinical 
significance can enroll at the discretion of the investigator.)
17)Females of childbearing potential (as defined in Appendix 6for Cohorts 1 -5, and 
Appendix 7for Cohorts 6 - 8) must have a negative serum pregnancy  test at screening .
18)Male and f emale subjects of childbearing potential who engage in heterosexual intercourse 
must agree to utilize protocol specified method(s) of contrace ption as described in 
Appendix 6for Cohorts 1 -5, and Appendix 7for Cohorts 6 - 8.
19)Female subjects must refrain from egg donation and in vitro fertilization during treatment 
and until at least :
300days following the dose of study  drug , for Cohort s 1 – 5
7days following the last dose of Biktarvy  on the study , for Cohort s 6 – 8
20)Cohorts 1 
- 5:Male subjects must refrain from sperm donation during treatment and until at 
least 360 days following the dose of stud y drug .
Cohorts 6 - 8: Male subjects must refrain from sperm donation during treatment on the 
study .
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 33 13 June 20194.3. Exclusion Criteria (Parts A and B)
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study .
1)Anticipated to start HIV -1 therap y between Day s1 and 9
2)Participation in any  other clinical trial, including observational studies, without prior approval 
from the sponsor is prohibited while participating in this trial
3)Recent use of an y approved or investigational antiretroviral drugs within 12 weeks prior to 
screening
4)Have taken an y prescription medications or over -the-counter medications, i ncluding herbal 
products, within 42 day s prior to start of study  drug dosing without prior approval form the 
sponsor, with the exception of vitamins and/or acetaminophen and/or hormonal contraceptive 
medications
5)Known hy persensitivity  to the study drug, the metabolites or formulation excipients , or to 
B/F/TAF
6)A new AIDS -defining condition diagnosed within the 30days prior to screening (refer to
Appendix 5)
7)
Hepatitis C virus (HCV) antibody  positive and HCV RNA detectable
8) Chronic Hepatitis B Virus (HBV) infection, as determined b y either:
Positive HBV surface antigen and negative HBV surface antibod y, regardless of HBV 
core antibod y status, at the screening visit 
Positive HBV core antibody and negative HBV surface antibody , regardless of HBV 
surface antigen status, at the screening visit.
9) Pregnant or lactating females
10)Have an implanted defibrillator or pacemaker
11)Current alcohol or substance use judged b y the Investigat orto potentiall y interfere with 
subject study  compliance
12)A history  of malignancy  within the past 5 years (prior to screening) or ongoing malignancy  
other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non- invasive 
cutaneous squam ous carcinoma. Subjects with cutaneous KS are eligible, but must not have 
received an y systemic therapy  for KS within 42 days of Day  1 and must not be anticipated to 
require s ystemic therapy  during the study
13)Active, serious infections (other than HIV -1 infection) requiring parenteral antibiotic or 
antifungal therap y within 42 days prior to Day 1
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 34 13 June 20195. INVESTIGA TIONAL  MEDI CINAL  PRODUCT AND B/F/T AF
5.1. Randomization, Blinding and Treatment Codes
Part A
Subjects will be assigned a screening number at the time of consent. It is the responsibility  of the 
investigator to ensure that the subject is eligible for the study  prior to enrollment.
Following completion of screening procedures, eligible su bjects will be randomized in a 3 :1 ratio 
within each cohor t to receive either GS -6207 (n=6 ) or placebo (n=2) on Day 1, and assigned a 
subject number. 
All screening tests and procedures must be completed and reviewed b y the investigator prior to 
the administration of the study  drug on Day  1. Once a subject number has been ass igned to a 
subject, it will not be reassigned to another subject. I f necessary , replacement subjects may  be 
enrolled after discussion and approval from Sponsor. A new unique subject number will be 
assigned to the replacement subject. 
The study  pharmacist, or designee will remain unblinded throughout the study  to prepare the 
study  drug. The designated site staff administering the study  drug will also remain unblinded. 
For additional information on maintaining the study  blind, please refer to the study  Pharm acy 
Manual .The Pharmacokinetics File Administrator, or designee, who facilitates data transfer of
PK files between Gilead and vendors , will remain unblinded. 
Part B
Subjects will be assigned a screening number at the time of consent. It is the responsibi lity of the 
investigator to ensure that the subject is eligible for the study  prior to enrollment.
Following completion of screening procedures, eligible su bjects will be enrolled to receive TAF 
and will be assigned a subject number. 
All screening tests a nd procedures must be completed and reviewed by  the investigator prior to 
the administration of the study  drug on Day  1. Once a subject number has been assigned to a 
subject, it will not be reassigned to another subject. I f necessary , replacement subjects may  be 
enrolled after discussion and approval from Sponsor. A new unique subject number will be 
assigned to the replacement subject.
5.1.1. Procedures for Breaking Treatment Codes (Part A)
In the event of a medical emergency  where breaking the blind is required t o provide medical care 
to the subject, the investigator may  obtain treatment assignment directly  from the I WRS sy stem 
for that subject. Gilead recommends but does not require that the investigator contact the Gilead
medical monitor before breaking the blin d. Treatment assignment should remain blinded unless 
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 35 13 June 2019that knowledge is necessary  to determine subject emergency  medical care. The rationale for 
unblinding must be clearly explained in source documentation and on the case report form/ 
electronic case report form (eCRF), along with the date on which the treatment assignment was 
obtained. The investigator is requested to contact the Gilead medical monitor promptly  in case of 
any treatment unblinding .
All subjects will be followed until study  completion unless consent to do so is specificall y 
withdrawn b y the subject.
Gilead Pharmacovigilance and Epidemiology (PVE ) may  independently  unblind cases for 
expedited reporting of suspected unexpected serious adverse reactions (SUSARs).
5.2. Description and Handling GS-6207, TAF and B/F/TAF
5.2.1. Formulation
5.2.1.1. GS-6207 and P lacebo
GS-6207 injectable suspension, 100 mg/mL  is a sterile, preservative -free, white to off -
white to 
tan suspension for subcutaneous injection. In addition to the active ingredient, the suspension 
contains the fo llowing inactive ingredients: poloxamer 188, sodium chloride, phosphate buffer, 
and water for injection.
The placebo is a sterile, clear, colorless soluti on for subcutaneous injection. The solution 
contains the following inactive ingredients: poloxamer 188 , sodium chloride, phosphate buffer, 
and water for injection.
5.2.1.2. TAF
TAF tablets, 25 mg, are y ellow, round, film -coated tablets debossed with "GSI" on one side of 
the tablet and "25" on the other side of the tablet. In addition to the active ingredient, the tablets 
contain the following inactive ingredients: lactose monohy drate, microcry stalline cellulose, 
croscarmellose sodium, magnesium stearate, pol yviny l alcohol, titanium dioxide, polyethylene 
glycol, talc, and iron oxide yellow.
5.2.1.3. Bictegravir/Emtricitabine/ Tenofovir Alafenamide ( B/F/TAF , 50/200/25 mg)
Bictegravir /Emtricitabine /Tenofovir Alafenamide 
(B/F/TAF, 50/200/25 mg) tablets are 
capsule -shaped, film -coated purplish- brown, debossed with "GSI" on one side of the tablet and 
"9883" on the other side of the tablet. Each tablet core contains 50 mg of bictegravir, 200 mg of 
emtricitabine, and 25 mg of tenofovir alafenamide. I n addition to the active ingredients, the 
B/F/TAF tablets contain croscarmellose sodium, magnesium stearate, and microcry stalline 
cellulose. The tablet cores are film -coated with iron oxide red, iron oxide black, pol yethylene 
glycol, pol yvinyl alcohol, talc, and titanium dioxide.
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 36 13 June 20195.2.2. Packaging and Labeling
5.2.2.1. GS-6207 and P lacebo
GS-6207 injectable suspension, 100 mg/mL, and placebo solution are each filled into a 3 mL 
borosilicate glass vial and closed with a rubber stopper and aluminum seal with a poly propylene 
flip-off cap. Each single use vial contains sufficient volume (1.2 mL) to allow withdrawal of 
1mL of GS -6207 injectable suspension or placebo solution. 
The vials are labeled and placed into secondary  packaging for storage.
Study  drug to be distributed to centers in the US shall be labeled to meet requirements of the 
USFood and Drug Administration (FDA) and/or other local regulations as applicable.
5.2.2.2. TAF 
TAF tablets are packaged in white, high densit y poly ethylene(HDPE) bottles. Each bottle 
contains 30 tablets and a silica gel desiccant and poly ester packing material. Each bottle is 
enclosed with a white, continuous thread, child- resista nt poly propy lene screw cap with an 
induction- sealed and aluminum -faced liner.
Study  drug to be distributed to centers in the US shall be labeled to meet requirements of the 
USFood and Drug Administration (FDA) and/or other local regulations as applicable.
5.2.2.3. Bictegravir/Emtricitabine/Tenofovir Alafenamide ( B/F/TAF, 50/200/25 mg)
Bictegravir /Emtricitabine /Tenofovir Alafenamide (B/F/TAF, 50/200/25 mg) ispackaged in 
white, high densit y pol yethylene (HDPE) bottles. Each bottle contains 30 tablets, silica gel 
desiccant and pol yester packing material. Each bottle is enclosed with a white, continuous 
thread, child
-resistant poly propy lene screw cap with a n induction -sealed and aluminum -faced 
liner.
B/F/TAF to be distributed to centers in the US shall be labeled to meet requirements of the 
USFood and Drug Administration (FDA) and/or other local regulations as applicable.
5.2.3. Storage and Handling
5.2.3.1. GS-6207 and P lacebo
GS-6207 100 mg/mL injectable suspension and placebo solution vials should be stored 
refrigerated at 2 °C to 8 °C (36 °F to 46 °F). Storage conditio ns are specified on the label. Until 
dispensed for dosing, all vials of study  drugs should be stored in a securel y locked area, 
accessible only  to authorized site personnel. 
To ensure the sterility , stability , and proper identification, study  drug(s) should not be stored in a 
container other than the container in which they  were supplied.
Measures that minimize drug contact with the body should alway s be considered during 
handling, prepara tion, and disposal proc edures.
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 37 13 June 20195.2.3.2. TAF 
TAF tablets should be stored at controlled room temperature of 25°C (77°F); excursions are 
permitted between 15°C and 30°C (59°F and 86°F). Storage conditions are specified on the label.
Until dispensed to the subjects, all bottles of study  drugsshould be stored in a securely  locked 
area, accessible only to authorized site personnel. Measures that minimize drug contact with the 
body  should alway s be considered during handling, preparation, and disposal procedures.
5.2.3.3. Bictegravir/Emtricitabine/Teno fovir Alafenamide ( B/F/TAF, 50/200/25 mg)
Bictegravir /Emtricitabine /Tenofovir Alafenamide (B/F/TAF, 50/200/25 mg) stored at 
controlled room temperature of 25°C (77°F); excursions are permitted between 15°C and 30°C 
(59°F and 86°F). Storage conditio ns are specified on the label. Until dispensed to the subjects, all 
bottles of B/F/TAF should be stored in a securel y locked area, accessible only  to authorized site 
personnel.
To ensure the stabilit y and proper identification, B/F/TAF should not be stored in a container
other than the container in which they  were supplied. Keep the bottle tightly closed to protect
from moisture.
Measures that minimize drug contact with the body should alway s be considered during 
handling, preparation, and disposal procedures.
5.3. Dosage and Administration of GS -6207 (Part A , Cohorts 1 - 5)
Part A of this study  may  enroll up to 5 cohorts of approximately  8 unique subjects per cohort. All 
subjects will be enrolled a
fter the completion of screening procedures and following 
confirmation of study  eligibility . Within each Cohort (n=8) in Part A , subjects will be 
randomized in a 
3:1 ratio to receive active GS -6207 (n=6) or placebo (n=2) .
A single dose of GS -6207 or placebo will be administered subcutaneousl y (SC) in the abdomen 
on Day  1. GS -6207 doses may  be administered as multiple SC injections at different abdominal 
sites, as appropriate. In the case where multiple injections are administered for a given dose, the 
first and last injections should be no more than 30minutes apart. If neces sary for practical 
reasons, the period may  be extended up to 45 minutes .
Cohort Treat ment
1 150 mg GS -6207 or placebo
2 50 mg GS -6207 or placebo
3 450 mg GS -6207 or placebo
4 20mg GS -6207 or placebo
5 750mg GS -6207 or placebo
The Sponsor may  elect to hold dosing, or stop study  enrollment at any  time based on review of 
preliminary  safety  data.
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 38 13 June 2019The doses to be evaluated in Cohorts 2 through 5will be determined based on cumulative safet y 
(through at least Day 14), available PK and viral kinetic data from previous cohort sas well as
available safet y (through at least Day  14) and pharmacokinetic data from Study 
GS-US-200-4070 (Phase 1, first- in-human, single ascending dose study  of GS -6207 SC 
suspension formulation). Cohorts 2
-5may be initiated in parallel. Selected doses will be either 
lower than, or no more than 3 -fold higher than, previously  evaluated doses either in this study  or 
in Study  GS-US-200- 4070; the same SC suspension formulation is being administered in both 
studie s. The highest proposed dose in this study , GS-6207 900 mg, represents a 2 -fold dose 
escalation over GS -6207 450 mg, which has been shown to be safe and well tolerated in Study  
GS-US-
200-4070, based on a blinded review of safety  data. 
5.4. Dosage and Administr ation of TAF (P art B, Cohorts 6 
- 8)
Part B of this study  may  enroll up to 3 cohorts of approximately  8 unique subjects per cohort. All 
subjects will be enrolled after the completion of screening procedures and following 
confirmation of stud y eligibility .Within each Cohort (n=8) in Part B, subjects will be enrolled to 
receive active oral TAF.
A single dose of TAF will be administered orally on Day 1.
The Sponsor may  elect to hold dosing, or stop study  enrollment at any  time based on review of 
preliminary  safety  and PK data.
The doses to be evaluated in Cohorts 7 -8will be determined based on cumulative safet y 
(through at least Day  14), available PK and viral kinetic data from previous cohort s. Selected 
doses will be either lower than, or no more than 3 -fold higher than, previously  evaluated doses in 
this study . Cohorts 7 and 8 may  be run in parallel.
Observed TAF dosing is required at Day 1.
5.5. Prior and C oncomitant Medications
The following medications are excluded while subjects are participating in Part A :
Any prescription medications and over -the-
counter medications, including herbal products, 
with the exception of vitamins, and/or acetaminophen and/or ibuprofen and/or hormonal 
contraceptive medications. However, the short -term use of topical hy drocortisone cream or 
AD ointment to treat minor skin irritation due to ECG leads will be allowed. If a subject 
requires use of a disallowed medication, a reques t for such use must be reviewed by  the 
Sponsor and if approved, subjects may  continue to participate in the study . 
Any and all illegal or illicit drug use, including use of prescription drugs outside the care of 
the prescribing ph ysician.Cohort Treat ment
6 200 mg TAF
7 Up to 600 mg TAF
8 Up to 600 mg TAF
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 39 13 June 2019For Part A , if asubject discontinue sB/F/TAF between the Day  10and Day  225 visits, they  can 
switch to an alternative ARV regimen , which should not contain the following prohibited ARVs: 
Prohibited ARVsHIV Protease Inhibitors
RTV or COBI containing regimens
Efavirenz
Etravirine
Nevirapine
The following medications are excluded while subjects are participating in Part B : 
TAF is a substrate of P -glycoprotein (Pgp) and breast cancer resistance protein (BCRP) 
transporters {DESCOVY®2017}. Drugs that inhibit or induce Pgp or BCRP activity  may  
lead to increases or decreases, respectivel y, in TAF absorption. In vitro data suggest TAF 
may inhibit or induce CYP3A at doses up to 600 mg, however, give n its short half -life and 
transient exposure, clinically  relevant changes in CYP3A substrates are not expected 
following co -administration with a single dose 
TAF. 
Medications that are potent inhibitors or inducers of Pgp/BCRP are prohibited, and use of 
herbal/natural supplements are excluded while subjects are participating in this study . 
Table 5-1contains examples of medications that are to be excluded while subjects are 
participating in the stud y in Part B. As this table is not exhaustive, all con comitant 
medications are to be reviewed with the sponsor until Day  10. After Day  10, the investigator 
should follow the current US PIfor B/F/TAF {BIKTARVY® 2018
}.
Any and all illegal or illicit drug use, including use of prescription drugs outside the care of 
the prescribing ph ysician , are prohibited .
Table 5-1. List of medications that are prohibite d due to the potential for 
drug -drug interaction with TAF
Medication Class Disallowed Medications
Anti-arrhythmics Amiodarone, Dronedarone, Propafenone
Anti-anginal agents Ranolazine
Anti-biotics Clarithromycin
Anti-convulsants Carbamazepine, Oxcarbazepine, Phenobarbital, Phenytoin
Anti-fungals Itraconazole
Anti-malarial s Quinidine
Anti-mycobacterials Rifapentine, Rifabutin, Rifampin
Anti-retroviral agents Any antiretroviral drug that is not part of the study regimen
Beta blockers Carvedilol
Ca channel blocker s Verapamil
Herbal/Natural SupplementsSt. John ’s Wort, Echinaccea, Milk thistle (i.e., silymarin), Chinese herb sho -saiko -to 
(or Xiao -Shai -Hu-Tang)
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 40 13 June 20195.6. Dispensing, Accountability, and Disposal or Return of GS-6207 and TAF 
(study drug s) and B/F/TAF
The investigator (or designee, eg, stud
y center pharmacist) will acknowledge receipt of the stud y 
drugsand B/F/TAF (after reviewing the shipment’s content and condition) from Gilead 
(ordesignee). The investigator will maintain an accurate inventory  of al l study  drug and 
B/F/TAF. The stud y drug will be administered at the study  center b y qualified study center staff. 
The dose of stud y drug administered to subjects in the clinic under the supervision of staff will 
be accuratel y recorded on the Study  Drug Ac countability  form provided by Gilead (or on 
equivalent documentation maintained by  the study  center), which indicates the date and quantit y 
of each dosage formulation dispensed to individual subjects.
Where possible, study  drug and B/F/TAF should be destro yed at the site. If the site does not have 
acceptable procedures in place for drug destruction, arrangements will be made between the site 
and Gilead Sciences (or Gilead Sciences’ representative) for return of unused study  drug supplies
and B/F/TAF. The st udy monitor will provide instructions for return.
The study  monitor will evaluate each study  center’s study  drug disposal procedures and provide 
appropriate instruction for destruction of unused study drug supplies. If the site has an 
appropriate standard operating procedure (SOP) for drug destruction as determined by  Gilead , 
the site may  destroy  used (empty  or partiall y empty) and unused stud y drug supplies in 
accordance with that site’s approved SOP. A cop y of the site’s approved SOP will be obtained 
forcentral files.
If study  drug or B/F/TAF is destroy ed on site, the investigator must maintain accurate records for 
all drug destro yed. Records must show the identification and quantit y of each unit destroyed, the 
method of destruction, and the person who d isposed of the drug s. Upon study  completion, copies 
of the study  drug accountability  records must be filed at the site. Another copy  will be returned 
to Gilead. Refer to the Pharmacy  Binder for study  drug disposal/return instructions. The study  
monitor wil l review study drug supplies and associated records at periodic intervals.
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 41 13 June 20196. STUDY  PROCEDURES
The study  procedures to be conducted for each subject enrolled in the study  are presented in 
tabular form in Appendix 2and described in the text that follows. Additional information is 
provided in the study  procedures manual.
The investigator must document any deviation from protocol procedures and notify  the sponsor 
or contract research organization (CRO).
6.1. Subject Enrollment and Treatment Assignment
Entry  into screening does not guarantee enrollment into the study . In order to manage the total 
trial enroll ment, Gilead, at its sole discretion, may suspend screening and/or enrollment at an y 
site or trial -wide at any  time.
6.2. Pretreatment Assessments
6.2.1.
Screening Visit
Subjects will be screened within 42 days prior to Day 1 to determine eligibility  for participation
in the study . The following will be performed and documented at screening:
Obtain written informed consent
Obtain medical history  including history  of HIV -1 disease -related events and prior 
medications within 42 days of the screening visit
Complete phy sical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)
Vital signs measurement (blood pressure, pulse, respiration rate, and temperature)
12-lead ECG performed supine
Height and Weight
Obtain blood and urine samples as described in Section 6.6
Review of AEs and concomitant medications
Once eligibility  is confirmed, each subject will be ass igned a unique subject number. Once a 
subject number has been assigned to a subject, it will not be re assigned to any  other subject. 
Prior to or during the Day 1 visit in Part A the Investigator or designee will enroll the subject 
using the Interactive Web Response Sy stem (IWRS). In Part B , the Investigator will contact 
Gilead Sciences to obtain the subject number. The subject number assignment may  be performed 
up to 7days prior to the in -clinic Day  1 visit provided that all screening procedures have been 
completed and subject e ligibility  has been confirmed.
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 42 13 June 2019Subjects meeting all of the inclusion criteria and none of the exclusion criteria will return to the 
clinic within 42 daysafter screening for Day 1 assessments. Subjects will be instructed to fast 
overnight ( 6hours) prior to the Day 1 visit.
From the time of obtaining informed consent through the first administration of investigational 
medicinal product, record all serious adverse events (SAEs), as well as any adverse events 
related to protocol -mandated procedures on the adverse e vents case report form (eCRF). All 
other untoward medical occurrences observed during the screening period, including 
exacerbation or changes in medical history  are to be capture d on the medical history  eCRF. 
See
Section 7Adverse Events and Toxicity  Management for additional details.
6.3. Treatment Assessments
Subjects will be required to visit the clinic on Days 1, 2, 3, 4, 5 (Part B only, if possible ), 
6(Part B only, if possible ), 7, 8, 9, 10, 14, 29, 43, 57, 85, 113, 141, 169, 197 and 225 .
Subjects will be required to fast overnight ( >6 hours) 
prior to visit on Day s 1, 3, 7, 10, 85, 169, 
and 225 for laboratory  analy ses.
6.3.1. Day 1 
The following procedures are to be completed at the Day 1 visit prior to study  drug dosing.
Review of AEs and changes in concomitant medications
Complete phy sical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)
Vital signs measureme nt (blood pressure, pulse, respiration rate, and temperature)
Weight
12-lead ECG performed supine ( pre-dose)
Obtain blood and urine samples as described in Section 6.6(Note: all blood and urine 
samples should be collected pre -dose on Day  1, except for PK samples as noted in 
Section 6.6)
Part B: A single dose of TAF will be administered orally  on Day 1 at the study  center under 
fasted conditions, with 240 mL  of water following an overnight fast (no food or drink, except 
water, for at least 6 hours).
On Day  1, subjects will be restricted from food intake until after collection of the 4- hour 
blood draw. Additionally, subjects will be restricted from water consumption 1 hour before 
and 2 hours after dosing, except for the 240 mL of water given with the study  drug. Subject s 
will fast until 2 hours after study  drug administration. Water may  be freel y consumed 
following the 2 -hour blood draw and for the remainder of the collection period. Subjects may  
eat after the 4 hour post -dose blood draw.
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 43 13 June 20196.3.2. Assessments on Days 2, 3, 4, 7, 8, 9, 10, 14, 29, 43, 57, 85, 113, 141, 169, 197 
and 225
Subjects will be required to fast overnight ( >6 hours) 
prior to visit on Day s 3, 7, 1 0, 85, 
169and225for laboratory  analy ses.Study  visit Day s 29, 43, 57, 85, 113, 141, 169 and 197 may  
be completed within ± 2 days of the protocol -specified visit date. 
The following procedures are to be completed at all visits unless otherwise specified: 
Review of AEs and changes in concomitant medications
Symptom directed phy sical examination 
Vital signs measurement (blood pressure, pulse, respiration rate, and temperature)
Weight
12-lead ECG performed supine (Day s 2, 10, 29, 57, 85, 169 and 225)
Obtain blood and urine samples as described in Section 6.6
All subjects will initiate B/F/TAF on Day  10after completion of all assessments.
B/F/TAF will be dispensed at Day
s 10, 43, 85, 141 and 197. 
6.4. Early Study Discontinuation Assessments
If a subject discontinues their part icipation prior to Day  225, Earl y Termination Visit should be 
perfor med. 
However, if there are a nyabnormal 
laboratory  results indicating that there is a possible or 
probable causal relationship with the study  drug, every  attempt should be made to keep the 
subject in the study  and repeat those laboratory  tests weekly  (or as often as deemed prudent by  
the Investigator) until the abnormality  is resolved, returns to baseline, or is otherwise explained.
If this is not possible or acceptable to the subject or investigator, the subject may  be withdrawn 
from the study .
CCI
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 44 13 June 2019The following evaluations should be performed at the Early Termination Visit :
Review of AEs and changes in concomitant medications
Complete phy sical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)
Vital signs measurement (blood pressure, pulse, respiration rate, and temperature)
Weight
Obtain blood and urine samples as described in Section 6.6
Counsel subject regarding the importance of continuing a complete ARV therapy  in 
accordance to standard of care, and refer patient to an appropriate HIV treatment facility
6.5. Criteria for Discon tinuation of Study 
Study  may  be discontinued in the following instances:
Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical status to a significant degree. Following resolution of intercurrent illness, the subject 
may resume study  dosing at the discretion of the investigator.
Unacceptable toxicity , or toxicity  that, in the judgment of the investigator, compromises the 
ability  to continue study -specific procedures or is considered to not be in the subject’s best 
interest
Subject request to discontinue for an y reason
Subject noncompliance with B/F/TAF
Pregnancy  during the study ; refer to Appendix 6and Appendix 7
Discontinuation of the study  at the request of Gilead, a regulatory  agency  or an institutional 
review board or independent ethics committee (IRB/IEC)
6.6. Clinical Laboratory Assessmen ts
Blood and urine samples will be collected throughout the study  as outlined below, within 
Section 6, and in Appendix 2Study  Procedures Table.
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 45 13 June 20196.6.1. Blood Samples
Blood sample collection for the following laboratory  anal yses will be performed at every  
visit, unless specified:
Serum pregnancy  test (females of childbearing potential only). If the test is positive, the 
subject will not be randomized (Screening and Days 29, 57, 85, 113, 141, 169,
197and225)
Serum FSH test (required for female subjects who have stopped menstruating for 
≥ 12 months but do not have documentation of ovarian hormonal failure) 
(Screening only)
Urine pregnancy  test (females of childbearing potential only ). If the test is positive, 
confirmatory  serum test should be sent and study drug dosing should be delay ed until 
results obtained (Day 1 )
Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, 
amylase (reflex lipase tes ting is performed in subjects with total amy lase 1.5ULN)
(All visits except Days 2, 4, 8 and9). Subjects will be required to fast overnight 
(> 6 hours) prior to visit on Day s 3, 7, 10, 85, 169 and225.
Estimated glomerular filtration rate according to the Cockcroft- Gault formula for 
Creatinine clearance (All visits except Days 2, 4, 8 and9)
Male: (140 –age in years) (wt in kg) CLcr (mL /min)
72(serum creatinine in mg/dL)
Female: (140 –age in years) (wt in kg) 0.85  CLcr (mL/min)
72(serum creatinine in mg/dL)
Hematology  profile: complete blood count (CBC) with differential and platelet count
(Allvisits except Days 2, 4, 8 and9)
CD4+ cell count (Screening and Days 1, 10, 29, 43, 57, 85, 113, 141, 169, 197 and 225)
Plasma HIV -1 RNA . Any  subsequent HIV -1 genoty pe and phenot ype testing will be 
performed as described in 
Section 6.7.
HIV
-1 genot ype and phenoty pefor PR, RT, I N, and capsid (Scree ning only)
HIV-1 capsid genot ype and phenoty pe (Day 10)
HIV DNA genot yping (Days 85, 169 and 225)
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 46 13 June 2019Hepatitis B virus (HBV) serologies (HBV surface antigen, HBV core antibody , HBV 
surface antibod y)(Screening only)
Hepatitis C virus (HCVAb) serology (Screening only)
Plasma storage samples for safet yandvirology testing (HIV -1 capsid genoty pe and 
phenoty pe) (Not collected at Screening visit)
GS-6207 PK Sampling (Part A, Cohorts 1 – 5)
Blood samples to det ermine PK in plasma :
■The exact time of study  drug administration and the exact time points (date and 
24-hour clock) of collection of plasma samples must be carefully  recorded.
■Day 1: Time 0 (pre -dose) , 1, 2, 4, 8, 12 and 24 hours post dose (relative to stu dy drug 
dosing time) 
blood sample collection to determine pharmacokinetics (PK) in plasma
on Day  1 
■Days 3, 4, 7, 8, 9, 10, 14, 29, 43, 57, 85, 113, 141, 169, 197 and 225 :a single 
anytime PK sample will be collected.
TAF PK sampling (Part B, Cohorts 6 - 8): 
Plasma PK samples will be collected to determine PKof TAF and its metabolite, TFV, at 
the following time points relative to study  drug dosing:
■Day 1: 0 (pre -dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 and 48 hours po st dose.
■Days 4, 5 (if possible ), 6(if possible ), 7, 8, 9, and 10 at approximately  the same time 
in the morning as pre -dose on Day  1.
PBMC PK samples will be collected to determine PKof TFV- DPat the following time 
points relative to study  drug dosing:
■Day 1: 0 (pre -dose), 1, 2, 4, 6, 8, 12, 24 and 48 hours post dose.
■Days 4, 5 ( if possible ), 6(if possible ), 7, 8, 9, and 10 at approximately  the same time 
in the morning as pre -dose on Day  1.
CCI
GS-6207 and TAF 
Protocol GS-US -200-4072 
Gilead Sciences , Inc. 
6.6.2. Urine Sample s Final 
Amendment4 
Urine samples will be collec ted for the following labora to1y analyses at eve1y study visit , unless 
othe1wise specified: 
• Ur inalysis and urine Chemistiy: including color & clarity, speci fic gravity , pH, g lucose, 
ketones, bilimbin, urob ilinoge n, bloo d, niu-ite, leukocyte esterase and microsco pic 
(if microsco pic eleme nts are seen), urine prote in, albumin , creatinine, phosphate, calci um, 
magnesium and uric acid (All visits except Days 2, 4, 8 and 9) 
• Ur ine pregnancy test (females of childbear ing potentia l only). If the test is positive , 
confinnato1 y sernm test shou ld be sent and study diug dosing should be delayed until results 
obtained (Day 1) 
• Ur ine storage (All visits except Screenin g, Days 2, 4, 8 and 9) -
6.7. Mana gement ofVirolo gic Failure after Initiation of B/F/TAF on Day 10 
Subjects who exper ience either su boptimal virologic respo nse (SVR) or virologic rebound (VR) 
after initiating B/F/TAF , as defined below, will be considered to have virologic failure. 
6.7.1. Suboptimal Virolo gic Response (S VR) 
• H IV-1 RNA~ 50 copies/mL and less than l log10 HIV-1 RNA reduction from Day 10 at the 
Day 57 visit 
Following the first instance of SVR at Day 57, subjects will be asked to return to the clinic for a 
sched uled or unsched uled blood di·aw (2 to 3 weeks after first SVR visit) for confnmat ion of 
SVR. A pl asma sample from either the first instance or the SVR confmnation visit will be tested 
for HIV -1 caps id genotypic and phen otypic resistance. In addition, if SVR is confnmed, a 
plasma sample from the SVR confnmat ion visit will be tested for HIV- 1 PR, RT, and IN 
genotypic and phen otypic resistance. 
CONFIDENTIAL Page 47 13 June 2019 
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 48 13 June 20196.7.2. Virologic Rebound (VR) 
At any  visit, after achieving HIV -1 RNA < 50 copies/mL , a rebound in HIV -1 RNA to
≥ 50 copies/mL , which is subsequently  confirmed at the following schedule d orunscheduled 
visit; OR
At any  visit, a > 1 log 10increase in HIV -1 RNA from the nadir which is subsequently
confirmed at the following scheduled or unscheduled visit.
At any  visit after achieving HIV -1 RNA < 50 c opies/mL , if the HIV -1 RNA is ≥50 and
<
200copies/mL, a reflex HI V-1 RNA repeat test will be conducted on stored plasma samples, 
ifavailable. If the repeat result is < 50 copies/mL, no further action is required. If the repeat 
result is ≥ 50 copies/mL  subjects will be asked to return to the c linic for a scheduled or 
unscheduled blood draw (2 to 3 weeks after the date of the ori ginal test that resulted in HIV -1 
RNA VR) for confirmation of VR. 
A plasma sample from either the firstinstance or the VR confirmation visit will be tested for 
HIV-1 c apsid genot ypic and phenot ypic resistance . In addition, if VR is confirmed, a plasma 
sample from the VR confirmation visit will be tested for HIV -1 PR, RT, and IN genot ypic and 
phenoty pic resistance .
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 49 13 June 20197. ADVERSE EVENTS AND T OXICITY  MANAGEMENT
7.1. Definition sof Adverse Events, Adverse Reactions, and Serious Adverse 
Events
7.1.1. Adverse Events
An adverse event (AE) is any  untoward medical occurrence in a clinical study  subject 
administered a medicinal product ,which 
does not necessarily  have a causal relationship with th e
treatment. An AE can therefore be an y unfavorable and/or unintended sign, sy mptom, or disease 
temporally  associated with the use of a medicinal product, whether or not considered re lated to 
the medicinal product. AEs may  also include pre -or post-treatment complications that occur as a 
result of protocol specified procedures, lack of efficacy , overdose ,drug abuse/misuse reports , or 
occupational exposure .Preexisting events that increase in severit y or change in nature during or 
as a consequence of participation in the clinical study  will also be considered AEs.
An AE does not include the following:
Medical or surgical procedures such as surgery , endoscopy ,tooth extraction, andtransfusion.
The condition that ledto the procedure may  be an adverse event and must be reported.
Pre-existing diseases, conditions, or laboratory  abnormalities present or detected before the 
screening visit that donot worsen
Situations where an untoward medical occurrence has not occurred (e.g. ,hospitalization for 
elective surgery , social and/or convenience admissions)
Overdose without clinical sequelae (see Section 7.7)
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not an 
AE. I t is considered to be pre -existing and should be documented on the medical history  
eCRF.
7.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as a n event that, at any dose, results in the following:
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
In-patient hospitalization or prolongation of existing hospitalization
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 50 13 June 2019Persistent or significant disability /incapacit y
A congenital anomal y/birth def ect
A medicall y important event or reaction: such events may  not be immediately  
life-threatening or result in death or hospitalization but may  jeopardize the subject or may  
require intervention to prevent one of the other outcomes constituting SAEs. Medica l and 
scientific judgment must be exercised to determine whether such an event is a reportable 
under expedited reporting rules. Examples of m edically  important e vents include intensive 
treatment in an emergency room or at home for allergic bronchospasm; bl ood dy scrasias or 
convulsions that do not result in hospitalization; anddevelopment of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a 
medicall y important e vent and s ubject to expedited reporting 
requirements.
7.2. Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality  and severity , and for final review and confirmation of accuracy  of event information 
and assessments.
7.2.1. Assessment of Causality for Study Drugs and Procedures
The investigator or qualified subinvestigator is responsible for assessing t he relationship to IMP
therap y using clinical judgment and the following cons iderations:
No: Evidence exists that the adverse event has an etiology  other than the IMP. For SAEs, an 
alternative causality must be provided (eg, pre -existing condition, underl ying disease, 
intercurrent illness, or concomitant medication).
Yes:There is reasonable possibility  that the event may  have been caused by the 
investigational medicinal product.
It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of adverse event reporting. 
The relationshi p to study  procedures (eg, invasive procedures such as venipuncture or biops y) 
should be assessed using the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the study  procedure.
Yes: The adverse event occurred as a result of protocol procedures (eg., venipun cture ).
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 51 13 June 20197.2.2. Assessment of Severity
AE severit y should be recorded and graded according to the Gilead Grading Scale for Severity of
Adverse Events and Laboratory  Abnormalities ( Appendix 4). 
The distinction between the seriousness and the severity  of an adverse event should be noted.
Severe is a measure of intensity ; thus, a severe reaction is not necessaril y a serious reaction. For
example, a headache may be severe in intensity
, but would not be classified as serious unless it
met one of the criteria for serious events.
7.3. Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to Gilead 
Requirements for collection prior to study  drug initiation:
After informed consent, but prior to administration of study  drug , the following t ypes of events 
should be reported on the case report form (eCRF): all SAEs and adverse events related to 
protocol -mandated procedures.
Adverse Events
Following administration of study  drug , all AEs, regardless of cause or relationship, that occur 
on or before the last posttreatment follow- up visit, or in the case of earl y termination, 225days 
after the administration of study  drug must be reported to the eCRF database as instructed.
All AEs should be followed up until resolution or until the adverse event is stable, if possible. 
Gilead Sciences may  request that certain AEs be followed bey ond the protocol defi nedfollow up 
period.
Serious Adverse Events
All SAEs, regardless of cause or relationship, that occur safter the subject first consents to 
participate in the stud y (ie, signing the informed consent) and throughout the duration of the 
study , including the protocol -required post treatment follow -up period, must be reported to the 
eCRF database and Gilead Pharmacovigilance and Epidemiology  (PVE) as instructed. This also 
includes an y SAEs resulting from protocol- associated procedures performed after informed 
consent is signed.
Any SAEs and deaths that occur on or before the last post -treatment follow -up visit, or in the 
case of earl y termination, 225 days after the administration of study  drug , regardless of causality , 
should also be reported. 
GS-6207 and TAF 
Protoco l GS-US -200-4072 
Gilead Sciences , Inc. Final 
Amendment4 
Investigators are not obligated to active ly seek SAEs after the protocol defined follow up period. 
However , if the investigator learns of any SAEs that occur after study paiiic ipation has 
concluded and the event is deemed relevant to the use ofIMP, he/she shou ld promptly docume nt 
and report the event to Gilead PVE . 
• A ll AEs and SAEs will be recorded in the eCRF database within the timeli nes outlined in the 
eCRF completion guideline. 
Electro nic Serious Adverse Event ( eSAE) Repo1i ing Process 
• Site perso nnel record all SAE data in the eCRF database and from there transmit the SAE 
infonnation to Gilead PVE within 24 hours of the investigato r's knowledge of the event. 
Detai led instructio ns can be foun d in the eCRF completio n guidelines. 
• If it is not possible to record and su bmit the SAE info1mat ion electr·o nically, beca use the 
eCRF database cannot be accessed or is not available (including at study staii) , record the 
SAE on the paper serious adve rse event repo1i ing fonn and submit within 24 hours to: 
Gilead PVE contact infonnation: Emai l: 
Fax: PPD 
PPD 
• As soon as it is poss ible to do so, any SAE reported via pape r must be tr·anscr ibed into the 
eCRF Database accord ing to instructions in the eCRF completio n guidelines. 
• If an SAE has been repo1ie d via a paper fonn because the eCRF database has been locked, 
no finiher action is necessaiy. 
• For fatal or life-threate ning events, copies of hospital case repo1is, autopsy repo1is, and other 
documents ai· e also to be submitted by e-mail or fax when r equested and applicab le. 
Transmissio n of such docume nts shou ld occur without personal subject identificatio n, 
maintain ing the traceabi lity of a docume nt to the su bject identifiers . 
• Additio nal infonnation may be requested to ensure the ti mely comp letion of accurate safety 
repo1is. 
• Any medicatio ns necessaiy for tr·eatine nt of the SAE must be recorde d onto the concomitant 
medicat ion section of the su bject's eCRF and the event description section of the SAE fonn. 
CONFIDENTIAL Page 52 13 June 2019 
GS-6207 and TAF 
Protoco l GS-US -200-4072 
Gilead Sciences , Inc. 
Standard of Care Adv erse Event Reporting Final 
Amendment4 
This is a study in which B/F/TAF will be administered as standard of care treatme nt for HIV. 
Investigators are en couraged to repo1i any special situatio ns, including preg nancy, and ad verse 
events associated with B/F/TAF or any other collllllercia lly available Gilead prod uct 
admin istered as part of standard-of-ca re treatme nt to Gilead PVE. 
Gilead PVE conta .ct infonnation: Emai l: 
Fax: 
7.4. Gilead Reportin g Requirem ents IPIPD 
IPIPD 
Depe nding on rel evant local legislatio n or r egulations, including the applicable US FDA Code of 
Federal Regulations , the EU Clinical Trials Directive (2001/20/EC) and releva nt updates, and 
other countiy-spec ific legislation or regulations, Gi lead may be required to expedite to 
worldwide regulato1 y agencies repo1is of SAEs , serious adverse dmg react ions (SADRs ), or 
suspected unexpected serious adverse reactio ns (SUSARs) . In accordance with the EU Clinical 
Trials Direct ive (2001/20/EC) , Gilead or a specified designee will notify worldwide regulato 1 y 
agencies and the relevant IEC in concerned Member States of applicable SUSARs as outlined in 
cmTent regulations. 
Assessme nt of expectedness for SAEs will be determined by Gilead using reference safety 
infonnatio n spec ified in the investigato r's broc hure or relevant local label as applicable. 
All investigators will receive a safety letter notify ing them of relevant SUSAR repo1is associated 
with any study IMP. The investigato r shou ld notify the IRB or IEC of SUSAR repo1is as soon as 
is pract ical, wh ere this is required by local regu lato1 y agencies, and in acco rdance with the local 
institutio nal policy. 
7.5. Clinical Laborator y Abnormalitie s and Other Abnormal Assess ment s 
Laborato 1 y abno1malities without clinical significance are usually not recorded as AEs or SAEs . 
However , laborato1y abno nnalities ( eg, clinical cheinistiy , hemato logy, and urine cheinistiy) 
independe nt of the underlyi ng medical cond ition that require medical or surgical interve ntion or 
lead to investigatio nal study disco ntinuation must be recorded as an AE, as well as an SAE , 
if applicab le. In addition, laborato 1 y or other abnonnal assessme nts ( eg, ECG, X-rays , vital 
signs) that are associated with signs and/or sympto ms must be recorded as an AE or SAE if they 
meet the definition of an AE ( or SAE) as descr ibed in Sections 7 .1.1 and 7 .1.2. If the laborato1y 
abno1mality is pa1i of a syndrome, record the syndrome or diagnosis (ie , aneinia) , not the 
laborato1y result (ie, decreased hemog lobin). 
CONFIDENTIAL Page 53 13 June 2019 
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 54 13 June 2019Severity  should be recorded and graded according to the GSI Grading Scale for Severit y of 
Adverse Events and Laboratory  Abnormalities ( Appendix 4). F or AEs associated with laboratory  
abnormalities, the event should be graded on the basis of the c
linical severity in the context of 
the underl ying conditions; this may  or may not be in agreement with the grading of the 
laboratory  abnormality .
7.6. Toxicity Management 
All clinical and clinicall
y significant laboratory toxicities will be managed according to uniform 
guidelines detailed in Appendix 3, and as outlined below.  
Clinical events and clinically
 significant laboratory  abnormalities will be graded according to 
the Gilead Grading Scale for Severit y of Adverse Events and Laboratory Abnormalities 
(Appendix 4). 
Treatment -emergent toxicities will be noted by the investigator and brought to the attention 
of the Gilead medical monitor. Whether or not considered treatment -related, all subjects 
experiencing AEs must be monitored periodically as clinically  indicated, until sy mptoms 
subside, and until any abnormal laboratory  values have resolved or returned to baseline levels 
or they  are considered irreversible, or until there is a satisfactory  explanation for the changes 
observed .
Grade 3 and 4 clinicall y significant laboratory  abnormalities should be confirmed by repeat 
testing within 3 calendar day s of receipt of results, unless such a delay  is not consistent with 
good medical practice.
Any questions regarding toxicity  management should be directed to the Gilead medical monitor.
7.7. Special Situations Reports
7.7.1. Definitions of Special Situations
Special situation reports includ e all 
reports of medication error, abuse, misuse, overdose , reports 
of adverse events associated with product complaints ,and pregnancy  reports regardless of an 
associated AE.
Medication err or is an y unintentional error in the prescribing, dispensing ,or administration of a 
medicinal product while in the control of the health care provider , subject, or consumer.
Abuse is defined as persistent or sporadic intentional excessive use of a medici nal product b y a 
subject.
Misuse 
is defined as an y intentional andinappropriate useof a medicinal p roduct tha t is not in 
accordance with the protocol instructions or the local prescribing information .
CCI
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 55 13 June 2019An overdose is defined as an accidental or intentiona l administration of a quantity  of a medicinal 
product given per administration or cumulatively  which is above the maximum recommended 
dose as per protocol or in the product labelling (as it applies to the daily  dose of the subject in 
question). In cases of a discrepancy  in drug accountability , overdose will be established only  
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy  except in cases in which the investi gator has 
reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product.
Occupational exposure with an AE is defined as exposure to a medicinal product as a result of
one’s professional or non -professional occupation.
7.7.2. Instructions for Reporting Special Situations
7.7.2.1. Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study  subjects 
that are identified after 
administration of study  drug and throughout the study , including the post study drug follow - up 
period, to the Gilead PVE using the pregnancy  report form within 24 hours of becoming aware 
of the pregnancy .
Refer to Section 7.3and the eCRF completion guidelines for full instructions on the mechanism 
of pregnancy  reporting.
The pregnancy  itself is not considered an AE nor is a n induced elective abortion to terminate a 
pregnancy  without medical reasons.
Any premat ure termination of pregnancy  (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported with in 24 hour s as an 
SAE. The underl ying medical reason for this procedure should be recorded as the AEterm.
A spontaneous abortion is alway s considered to be an SAE and w ill be reported as described in 
Section 7.1.2. Furthermore, an y SAE occurring as an adverse pregnancy  outcome post study
must be reported to Gilead PVE .
The subject should receive appropriate monitoring and care until the conclusion of the 
pregnancy . The outcome should be reported to or Gilead PVE using the pregnancy  outcome 
report form. If the end of the pregnancy  occurs after the study  has been completed
, the outcome 
should be reported directly  to Gilead PVE . Gilead PVE contact information is as follows: 
Email:  and Fax: 
PPD
PPD
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 56 13 June 2019Pregnancies of female partners of male stud y subjects exposed to Gilead or other study  drugs 
must also be reported and relevant information should be submitted to Gilead PVE using the 
pregnancy  and pregnancy  outcome forms within 24 hours. Monitoring of the subject should 
continue until the conclusion of the pregnancy . If the end of the pregnancy  occur s after the study  
has been completed, the outcome should be reported directl y to Gilead PVE , 
faxnumber  or email  
Refer to Appendix 6for Pregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements.
7.7.2.2. Reporting Other Special Situations
All other special situation reports must be repo rted on the special situations report form and 
forwarded to Gilead 
PVE within 24 hours of the investigator becoming aware of the situation. 
These reports must consist of situations that involve study  IMPand/or Gilead concomitant 
medications, but do not apply  to non-Gilead concomitant medications. 
Special situations involving non-Gilead concomitant medications donot need to be reported on 
the special situ ations report form; however, for special situations that result in AEs due to a 
non-Gilead concomitant medication , the AE should be reported on the AE form . 
Any inappropriate use of concomitant medications prohibited by  this protocol should not be 
reported as “misuse,” but may  be more appropriately  documented as a protocol deviation.
Refer to Section 7.3and the eCRF completion guidelines for full instructions on the mechanism 
of special situations reporting.
All clinical sequelae in relation to these special situa tion reports will be reported as AEs or SAEs 
at the same time using the AE eCRF and/or the SAE report form. Details of the sy mptoms and 
signs, clinical management, and outcome will be reported, when available.
PPD
PPD
GS-6207 and TAF 
Protocol GS-US -200-4072 
Gilead Sciences , Inc. 
8. STATISTICAL CONSIDERATIONS 
8.1. Analysis Objectives and Endpoints 
8.1.1. Analysis Objectives 
Part A (Cohorts 1 -5): Final 
Amendment4 
The prima1 y analysis objective of this study is to evaluate the sho1t-tenn antivi ral activity of 
GS-6207 compared to placebo admini stered subcutaneously (SC) in the abdomen on D ay 1, with 
respect to th e maximum reduction of plasma HIV-I RNA (log1 0 copies/mL) from D ay 1 through 
Day 10 in HIV-I infected adult subjects who are antiretroviral treatment na'ive or are experienced 
but caps id inhibi tor (CAI) na'ive. 
The seco ndaiy analysis objectives of this study are to investigate the safety and tolerability of 
GS-6207 as compai ·ed to placebo, to characterize the plasma phaimacokinetic (PK) of GS-6207 
and the P K/phaim acodynamic (PD) (or dose-response) relationship betwee n GS-6207 
concentration at Day 10 and the viral dynainics of HIV- I , to dete1min e the num ber and 
percentage of su bjects ever achieving HIV-I RNA < 50 copies/mL by Day 10, and to examine 
any emer gence of CAI resistance. 
Part B (C ohorts 6 -8): 
The prima1 y analysis objective of this study is to evaluate the sho rt-tenn antiviral activity of a 
single dose of oral T AF with r espect to th e maximum reduction of plasma H IV-I RNA 
(log10 copies/mL) from D ay 1 through Day 10 in HIV-I infected adult subj ects who ai·e 
antiretroviral treatment na'ive or are expe rienced but witho ut resistance to TAF . 
The seco ndaiy analysis ob jectives of this study are to investigate the safety and tolerabil ity of 
TAF, to chai·acterize the PK of TAF, and to exainin e any emer gence ofTAF resistance. 
8.1.2. Primar y Endpoint 
The prima1 y endpo int is the m aximum reduction of plasma HIV-I RNA (log1 0 copies/mL) from 
Day 1 through D ay 10. 
CON FIDENTIAL Page 57 13 June 2019 
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 58 13 June 20198.1.3. Secondary Endpoint
Secondary endpoints include: 
Incidences of adverse events and graded laboratory  abnormalities
PK parameters of GS -6207 (Part A) and TAF (and its metabolites, as appropriate) (Part B)
Correlation between Ct(concentration at Day  10) of GS - 6207 (Part A) and the maximum 
reduction of plasma HIV -1 RNA ( log 10copies/mL) from baseline through Day  10
Number and percentage of subjects ever achieving HIV
-1 RNA < 50copies/mL  by Day 10
(Part A)
Incidences of 
any emergence of CAI  resistance (Part A)
Incidences of an y emergence of TAF resistance (Part B)
8.1.4. Other Endpoints of Interest
The correlati on between AUC of TAF , and its metabolites, as appropriate, and the maximum 
reduction of plasma HIV -1 RN A (log 10copies/mL) from baseline through Day 10. 
8.2. Analysis Conventions
8.2.1. Analysis Sets
Analy sis sets define which subjects are included in an anal ysis. The assignment of subjects to 
analysis sets will be done before the study  blind is broken for anal ysis.
8.2.1.1. E fficacy
The primary  anal ysis set for efficacy  anal ysis isdefined as full anal ysis set (FAS), which 
includes all subjects who are randomized and receive full dose of randomized study  drug . 
Subjects with major eligibility  violations that are identifiable ba sed on pre -randomization 
characteristics may be excluded. Subjects will be grouped according to the treatment to which 
they are randomized.
8.2.1.2. Safety
The primary  anal ysis set for safety
 anal yses isdefined as safety  anal ysis set, which includes all 
subjects who are randomized and receive any dose of study  drug. Subjects who receive treatment 
other than that intended will be anal yzed acc ording to treatment received.
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 59 13 June 20198.2.1.3. Pharmacokinetics
The primary  anal ysis set for PK anal yses is defined as GS -6207 or TAF PK anal ysis set, which 
includes all subjects who are randomized, receive any  dose of GS -6207 or TAF , and have at l east 
1 nonmissing post baseline concentration value for GS-6207 or TAF , or its metabolites . 
8.2.1.4. Pharmacokinetic/Pharmacody namic Anal ysis Set 
ThePK/PD anal ysis set includes all subjects who are in full analy sis set and have both 
nonmissing 
Ctof GS -6207 and the maximum reduction of plasma HIV -1 RNA (log 10copies/mL) 
from Day 1 through Day  10.
8.3. Data Handling Conventions
Logarithm (base 10) transformation will be applied to HIV -1 RNA levels for efficacy  anal ysis. 
Natural logarithm transformation for all PK parameters of GS -6207, TAF , and its metabolites 
(eg, Cmax, Ct, and AUC 0
-t, as applicable ) will be applied for pharmacokinetic anal ysis.
For summary statistics, PK concentration values below the limit of quantitation (BLQ) will be 
treated as zero at pre -dose and one -half of the lower limit of quantitation (LLOQ) for post dose 
time points.
Laboratory  data that are continuous in nature but are less than the LLOQ or above the upper limit 
of quantitation will be imputed to the value of the lower or upper limit minus or plus 1 
significant digit, respectively  (eg, if the result of a continuous laboratory  test is < 20, a value of
19 will be assigned; if the r esult of a continuous laboratory  test is < 20.0, a value of 19.9 will be 
assigned).
8.4. Demographic Data and Baseline Characteristics
Demographic and baseline characteristics will be summarized and descriptive statistics will be 
provided.
Demographic summaries will include sex, race, ethnicity , and age.
Baseline data will include a summary  of bod y weight, height, and bod y mass index.
8.5. Efficacy Analysis
8.5.1. Primary Analysis
Data from the placebo recipients in all cohorts will be combined to form one placebo group for
the purpose of anal ysis. Each of the GS -
6207 and TAF treatment group will be compared to the 
pooled placebo group with respect to the primary  efficacy  endpoint, the maximum reduction of 
plasma HIV -1 RNA (log 10copies/mL ) from Day 1 through Day  10, using t he 2-sided t -test 
conducted at an alpha level of 0.05.
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 60 13 June 20198.5.2. Secondary Analyses
Correlation between Ctof GS -6207 and the maximum reduction of HIV -1 RNA
(log 10copies/mL ) from Day 1 through Day  10will be assessed using the Pearson correlation 
analysis. Anal ysis will be done for each tr eatment group.
The percentage of subjects ever achieving HIV -1 RNA < 50 copies/mL by  Day  10(for Part A 
only) will be summarized by  treatment group. Fisher exact tes
t will be used for comparison 
between treatment groups.
Percentage of subjects with any  emergence of CAI resistance and TAF resistance, respectivel y, 
will be summarized by  treatment group.
8.6. Safety Analysis
All safet y data collected on or after the first dos e date will be summarized by  treatment 
according to the stud y drug received. Data for the pretreatment period will be included in data 
listings.
8.6.1. Duration of Exposure
A subject’s extent of exposure to study  drug data will be generated from the study  drug 
administration 
eCRF form. Exposure data will be listed.
8.6.2. Adverse Events
Clinical and laboratory  adverse events will be coded using the Medical Dictionary  for 
Regulatory  Activities (MedDRA). Sy stem Organ Class (SOC), High -Level Group Term 
(HLGT), High -Level Term (HL T), Preferred Term (PT), and Lower -Level Term (LLT) will be 
attached to the clinical database.
Events will be summarized on the basis of the date of onset for the event. A treatment -emergent 
adverse event will be defined as an y adverse event that begin son or 
after the date of first dose of 
study  drug .
Summaries (number and percentage of subjects) of treatment -emergent adverse events (b y SOC, 
and PT) will be provided by  treatment group. Additional summaries will include summaries for 
adverse event s by grade, Investigator’s assessment of relationship to study  drug, and effect on 
study  drug dosing. 
8.6.3. Laboratory 
Evaluations
Selected laboratory  data will be summarized using onl y observed data. Data and change from 
baseline at all scheduled time points w ill be summarized.
Graded laboratory  abnormalities will be defined using the grading scheme defined in Grading of 
laboratory  abnormalities attached in Appendix 4. 
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 61 13 June 2019Incidence of treatment -emergent laboratory  abnormalities, defined as values that increase at least 
1 toxicity  grade from bas eline at an y time post baseline ,will be summarized by  treatment group. 
If baseline data are mis sing, an y graded abnormality  (ie, atleast a Grade 1) will be consider ed 
treatment emergent. The post baseline maximum toxicity  grade will be sum marized by  
laboratory  parameter.
Laboratory  abnormalities that occur before the first dose of study  drug will be included in a data 
listing.
8.6.4. Other Safety Evaluations
Vital sign and safet y ECG data will be summarized and/or listed as appropriate.
8.7. Pharmacokinetic Analysis
The plasma concentration data of GS -6207 and TAF , and its metabolites, will be summarized by  
nominal sampling time and treatment using descriptive statistics. Pharmacokinetic and PBMC 
parameters will be listed and summarized using descriptive statistics ( eg,sample size, arithmetic 
mean, geometric mean, % coefficient of variation, standard deviation, median, minimum, and 
maximum) by  treatment group. The concentrations of the study  drug in plasma over time w ill be 
plotted in semi -logarithmic and linear formats as mean standard deviation and median 
(Q1, Q3), respectivel y.
8.8. Sample Size
Part A: A sample size of 6 subjects in each GS -6207 treatment group and a total of 10placebo 
subjects from all cohorts combined will provide 99% power to detect a treatment difference of 
2.79 log 10copies/mL  in maximum reduction of HIV - 1 RNA between at least one of the GS -6207 
treatment groups and the plac ebo group. In this power analysis, it is assumed that a common 
standard deviation for maximum reduction in HIV- 1 RNA is 0.526 log 10copies/mL  (based on 
Study  GS-US-141-1219) and a 2- sided t-testis conducted at an alpha level of 0.05.
Part B: A sample size of 8 subjects in each TAF dose group and a total of 10 subjects in the 
placebo group will provide 99% power to detect a treatment difference of 1.43 log 10copies/mL 
in maximum reduction of HIV -1 RNA between at least one of the TAF dose groups and the 
placebo group from Part A. In this power anal ysis, it is assumed that a common standard 
deviation for maximum reduction in HIV- 1 RNA is 0.52 log 10 copies/mL  (based on Studies 
GS-US-120- 0104 and GS -US- 120-1101) and a 2 -sided t -test is conducted at an alpha leve l of 
0.05.
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 62 13 June 20198.9. Analysis Schedule
Interim Unblinded Analyses
Prior to the final anal ysis,a few selected individuals from Gilead will be unblinded t o assess the 
interim safet y, efficacy , and PK of study  drug .This group will consist of at least 
one
representative from Clinical Research, Biostatistics, Clinical Pharmacology , and 
Pharmacovigilance/Epidemiology , and may  include other personnel as necessary .Details of 
unblinding (eg, memberships, responsibilities, analy sis schedules) will be defined in a charter.
1) To select the doses for Cohorts 2 through 5 in Part A
After at least 50% of the subject sand/orafter all subjects within each cohort complete the 
Day 10 visit, the Sponsor will conduct interim unblinded anal yses to select the GS-6207 doses to 
evaluate in each 
subsequent cohort . The Sponsor will review cumulative safet y (through at least
Day 14), available viral kinetic, and available PK data. The results from these anal yses may  be 
submitted to regulatory  agencies to facilitate the clin ical development program or to scientific 
meetings or journals to disseminate the findings. 
2) To select the doses for Cohorts 7 and 8 in Part B
After at least 50% of the subjects in each cohort and/or after all subjects within each cohort 
complete the Day  10 visit, the Sponsor will conduct interim anal yses to select the TAF doses to 
evaluate in each subsequent cohort. The Sponsor will review cumulative safet y (through at least
Day 14), available viral kinetic, and available PK data. The results from these an alyses may  be 
submitted to regulatory agencies to facilitate the clinical development program or to scientific 
meetings or journals to disseminate the findings.
3)To select the dose(s) for further clinical development
After the last subject in the study  completes Day  10 visit, the Sponsor may conduct an interim 
unblinded anal ysis of cumulative safet y, viral kinetic, and PK data to select the dose(s) for 
further clinical developmen
t (e.g. Phase 2 or 3 studies).
Final analysis
The Sponsor will conduct a final anal ysis of all data after the last subject in the study  completes 
the last visit (Day  225) or prematurely  discontinues from the study .
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 63 13 June 20199. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study  isconducted in accordance with the principles of the 
Declaration of Helsinki (as amended in Edinburgh, Toky o, Venice, Hong Kong, and 
South Africa), International Conference on Harmonisation (I CH) guidelines, or with the laws and 
regulations of the country in which the research is conducted, whichever affords the greater 
protection to the study  subject. The investigator will ensure adherence to the basic principles of 
Good Clinical Practice, as outlined in 21 CFR 312, subpart D, “Responsibilities of Sponsors and 
Investigators,” 21 CFR, part 50, 1998, and 21 CFR, part 56, 1998.
The investigator and all applicable subinvestigators will comply  with 21 CFR, Part 54, 1998, 
providing documentation of their financial interest or arrangements with Gilead, or proprieta ry 
interests in the investigational drug under stud y. This documentation must be provided prior to 
the investigator’s (and any  subinvestigator’s) participation in the study . The investigator and 
subinvestigator agree to notify  Gilead of an y change in repor table interests during the study  and 
for 1 year following completion of the study. Study completion is defined as the date when the 
last subject completes the protocol
-defined activities.
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject information sheet s, or descriptions of the study  used to obtain 
informed consent) to an IRB. The investigator will not begin an y stud y subject activities until 
approval from the IRB has been documented and provided as a letter to the investigator.
Before implementation, th e investigator will submit to and receive documented approval from 
the IRBany modifications made to the protocol or any accompan ying material to be provided to 
the subject after initial IRBapproval, with the exception of those necessary to reduce immedia te 
risk to study  subjects .
9.1.3. Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study  and before undertaking an y stud y
-related procedures. The 
investigator must use the most current IRB approved consent form for docume nting written 
informed consent. Each informed consent (or assent as applicable) will be appropriatel y signed 
and dated b y the subject or the subject’s legally authorized representative and the person 
conducting the consent discussion, and also by  an impartial witness if required b y IRB or local 
requirements. The consent form will inform subjects about pharmacogenomic testing and sample 
retention, and their right to receive clinicall y relevant pharmacogenomic analysis results.
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 64 13 June 20199.1.4. Confidentiality
The investigato r must assure that subjects ’ anonymity  will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only  subject initials, date of birth, another 
unique identifier (as allowed b y local law) and an identification code will be recorded on an y 
form or biological sample submitted to the Sponsor, IRB,or laboratory . Laboratory  specimens 
must be labeled in such a way  as to protect subject identity  while allowing the results to be 
recorded to the proper subject. Refer to specific laboratory  instructions . NOTE :The investigator 
must keep a screening log showing codes, names, and addresses for all subjects screened and for 
all 
subjects enrolled in the trial. Subject data will be processed in accordance with all applicable 
regulations
The investigator agrees that all information received from Gilead, including but not limited to the 
investigator brochure, this protocol, eCRF , the IMP, and any  other study  information, remain the 
sole and exclusive property  of Gilead during the conduct o f the study  and thereafter. This 
information is not to be disclosed to any  third party  (except employ ees or agents directl y 
involved in the conduct of the study  or as required by  law) without prior written consent from 
Gilead. The investigator further agre es to take all reasonable precautions to prevent the 
disclosure b y any employee or agent of the stud y site to any  third party  or otherwise into the 
public domain.
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate and accurate rec ords to enable the conduct of the study  
to be fully  documented and the study data to be subsequently  verified. These documents should 
be classified into at least the following two categories: (1)investigator’s study  file, and 
(2)subject clinical source d ocuments.
The investigator’s stud y file will contain the protocol/amendments, CRF and query  forms, IRB 
and governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate docu ments and correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:
Subject identification (name, date of birth, gender);
Documentation that subject meets eligibility  criteria, ie, history , phy sical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);
Documentation of the reason(s) a consented subject is not enrolled
Participation in study  (including study  number);
Study  discussed and date of informed consent;
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 65 13 June 2019Dates of all visits;
Documentation that protocol specific procedures were performed;
Results of efficacy  parameters, as required b y the protocol;
Start and end date (including dose regimen) of IMP, including dates of dispensing and return;
Record of all adverse events and other safety  parameters (start and end date, and including 
causality  and severity );
Concomitant medication (including start and end date, dose if relevant; dose changes);
Date of study  completion and reason for earl y disc ontinuation, if it occurs .
All clinical study  documents must be retained b y the investigator until at least 2 years or 
according to local laws, whichever is longer, after the last approval of a marketing application in 
an ICH region (ie, United States, Eur ope, or Japan) and until there are no pending or planned 
marketing applications in an I CH region; or, if no application is filed or if the application is not 
approved for such indication, until 2 years after the investigation is discontinued and regulatory
authorities have been notified. Investigators may  be required to retain documents longer if 
specified 
by regulatory  requirements, by  local regulations, or by  an agreement with Gilead. The 
investigator must notify  Gilead before destro ying any  clinical stud y records.
Should the investigator wish to assign the stud y records to another part y or move them to another 
location, Gilead must be notified in advance.
If the investigator cannot provide for this archiving requirement at the study  site for any  or all of
the documents, special arrangements must be made between the investigator and Gilead to store 
these records securel y awa y from the site so that they  can be returned sealed to the investigator 
in case of a n inspection . When source documents are required for the continued care of the 
subject, appropriate copies should be made for storage away  from the site.
9.1.6. Case Report Forms
For each subject consented, an eCRF casebook will be completed b y an authorized study staff 
member whose training for this function is completed in EDC. The eCRF casebook will only  
capture the data required per the protocol sche dule of events and procedures. The 
Inclusion/Exclusion Criteria and Enrollment eCRFs should be completed only  after all data 
related to eligibility  have been recei ved. Subsequent to data entry , a stud y monitor will perform 
source data veri fication within the EDC sy stem. System -generated or manual queries will be 
issued to the investigative site staff as data discrepancies are identified b y the monitor or internal 
Gilead staff, who routinely  review the data for completeness , correctness, and consistency .The 
site coordinator is responsible for responding to the queries in a timel y manner, within the 
system, either b y confirming the data as correct or updating the orig inal entry , and providing the 
reason for the update (e.g. data entry  error). Original entries as well as any  changes to data fields 
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 66 13 June 2019will be stored in the audit trail of the sy stem. Prior to any  interim t ime points or database lock 
(asinstructed b y Gilead) , the investigator will use his/her log in credentials to confirm that the 
forms have been reviewed, and that the entries accuratel y reflect the infor mation in the source 
documents. At the conclusion of the trial, Gilead will provide the site with a read -only archive 
copy  ofthe data entered by  that site. This archive must be stored in accordance with the records 
retention requirements outlined in Section 9.1.5.
9.1.7. GS-
6207 and TAF (Investigational Medicinal Product or Study Drug) and 
B/F/TAF Accountability and Return
Where possible, IMP and B/F/TAF 
should be destroy ed at the site. If the site has an appropriate 
SOP for drug destruction as determined b y Gilead, the site may  destroy  used (empty  or partiall y 
empty ) and unused IMP and B/F/TAF supplies in accordance with that site’s approved SOP. A 
copy  of the site’s approved SOP will be obtained for central files. If IMP and/or B/F/TAF are
destroy ed on site, the investigator must maintain accurate records for all IMP and/or B/F/TAF 
destroy ed. Records must show the identification and quantity  of each unit destroy ed, the method 
of destruc tion, and the person who disposed of the I MP. Upon study  completion, copies of the 
IMP accountability  records must be filed at the site. Another copy  will be returned to Gilead. If 
the site does not have an appropriate SOP for drug destruction, used and un used IMP and 
B/F/TAF supplies are to be sent to the designated disposal facility  for eventual destruction. The 
study  monitor will provide instructions for return .
9.1.8. Inspections
The investigator will make available all source documents and other records for t his trial to 
Gilead’s appointed stud y monitors , toIRB, or to regulatory  authorit y or health authority  
inspectors.
9.1.9. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations des cribed in this protocol.
9.2. Sponsor Responsibilities
9.2.1. Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study  subjects , may  be 
made only  by Gilead. 
The investigator must submit a ll protocol modifications to the IRB in 
accordance with local requirements and receive documented IRB approval before modifications 
can be implemented.
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 67 13 June 20199.2.2. Study Report and Publications
A clinical study  report (CSR) will be prepared and provided to the regulatory agency . Gilead will 
ensure that the report meets the standards set out in the I CH Guideline for Structure and Content 
of Clinical Study  Reports (I CHE3). Note that an abbreviated report may  be prepared in certain 
cases.
Investigators in this study  may  communicate, orally  present, or publish in scientific journals or 
other scholarl y media only after the following conditions have been met:
the results of the study in their entiret y have been publicly disclosed b y or with the consent of 
Gilead in an abstract, manuscript, or presentation form or the stud y has been completed at all 
study  sites for at least 2 years
The investigator will submit to Gilead any  proposed publication or presentation along with the 
respective scientific journal or presentation forum at least 30 day s before submissi on of the 
publication or presentation. 
No such communication, presentation, or publication will include Gilead’s confidential 
information ( see Section 9.1.4).
Theinvestigator will comply  with Gilead’s request to delete references to its confidential 
information (other than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary .
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1.
Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, e.g. attendan ce at I nvestigator's Meetings. If require d under the applicable statutory  and 
regulatory  requirements, Gilead will capture and disclose to Federal and State agencies any  
expenses paid or reimbursed for such services, including an y clinical trial payments, meal, travel 
expenses or reimbursements, consulting fees, and any  other transfer of value.
9.3.2. Access to Information for Monitoring
In accordance with regulations and guidelines, the study  monitor must have direct access to the 
investigator’s source documentation in order to verify  the accuracy  of the data recorded in the 
eCRF .
The monitor is responsible for routine review of the eCRF at regular intervals throughout the 
study  to verify  adherence to the protocol and the completeness, consistency, and accuracy  of the 
data being entered on them. The moni tor should have access to an y subject records needed to 
verify  the entries on the eCRF . The investigator agrees to cooperate with the monitor to ensure 
that any  problems detected 
through an y type of monitoring (central, on site) are resolved.
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 68 13 June 20199.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of Gilead may  conduct inspections or audits of the 
clinical study . If the investigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to notify the Gilead medical monitor immediately. The investigator agrees to 
provide to representatives of a regulatory  agency  or Gilead access to records, facilities, and 
personnel for the effective conduct of an y inspection or audit.
9.3.4. Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the stud y at an y time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the appropriate 
regulatory  authorit y(ies), I RBs, and IECs. In terminating the study , Gilead and the investigator 
will assure that adequate consideration is given to the protection of the subjects’ interests.
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 69 13 June 201910. REFERENCES
BIKTARVY®, Gilead Sciences Inc. BIKTARVY® (bictegravir, emtricitabine, and tenofovir 
alafenamide) tablets, for oral use. US Prescribing Information (USPI). Foster 
City, CA. Revised: February .  2018:
Centers for Disease Control (CDC). HIV Surveillance Report: Diagnoses of HIV Infection in the 
United States and Dependent Areas, 2015. Volume 27. Available at: 
http://www.cdc.gov/hiv/library /reports/surveillance/ .  Accessed: 30 January.  
2017.
Claborn KR, Meier E, Miller MB, Leffingwell TR. A Sy stematic Review Of Treatment Fatigue 
Among HIV -Infected Patients Prescribed Antiretroviral Therap y. Ps ychology, 
health & medicine 2015;20 (3):1 -11.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 
1976;16:31-41.
DESCOVY®, Gilead Sciences Inc. DESCOVY®(emtricitabine and tenofovir alafenamide) 
tablets, for oral use. U. S. Prescribing Information. Foster City , CA. Revised: 
September.  2017:
Ruane PJ, Dejesus E, Berger D, Markowitz M, Bredeek UF, Callebaut C, et al. Antiviral 
Activity , Safet y, and Pharmacokinetics/Pharmacody namics of Tenofovir 
Alafenamide as 10 -Day Mono therap y in HIV -1-Positive Adults. J Acquir Immune 
Defic S yndr 2013;63 (4):449
-55.
Schneider E, Whitmore S, Gly nn KM, Dominguez K, Mitsch A, McKenna MT. Revised 
surveillance case definitions for HIV infection among adults, adolescents, and 
children aged <18 months and for HIV infection and AIDS among children aged 
18 months to <13 y ears--United States, 2008. MMWR Recomm Rep 2008;57 
(RR- 10):1-12.
STRI BILD®, Gilead Sciences Inc. STRIBILD® (elvitegravir, cobicistat, emtricitabine, tenofovir 
disoproxil fumarate) Tablets, for Oral Use. U. S. Prescribing Information. Foster 
City, CA. Revised: January .  2019:
The Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for 
Adults and Adolescents. Guidelines for the Use of Antiretroviral Agen ts in Adults 
and Adolescents L iving with HIV. Available at: 
http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf . Last 
Updated: 17 October.  2017.
UNAIDS. Fact Sheet 2016: Global Statistics -2015. Available at: 
http://www.unaids.org/en/resource s/documents/2016/UNAIDS_FactSheet .  2016.
VIREAD, Gilead Sciences Inc. VI READ® (tenofovir disoproxil fumarate) Tablets, for Oral Use. 
VIREAD® (tenofovir disoproxil fumarate) Powder, for Oral Use. U. S. 
Prescribing Information. Foster City , CA. Revised: Apr il.  2019:
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 70 13 June 201911. APPENDICES
Appendix 1. Investigator Signature Page
Appendix 2. Study Procedures Table
Appendix 3. Management of Clinical and Laboratory Adverse Events
Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Appendix 5. Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC Guidelines)
Appendix 6. GS-6207 Pregnancy Precaution s (Part A), Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
Appendix 7. TAF Pregnancy Precautions (Part B), Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
GS-6207 and TAF 
Protocol GS-US-200-4072 
Gilead Sciences, Inc. 
Appendix 1. Investigator Signature Page 
GILEAD SCIENCES, INC. 
333 LAKESIDE DRIVE 
FOSTER CITY, CA 94404 
STUDY ACKNOWLEDGEMENT Final 
Ame ndment4 
A Phase 1 b Randomi zed, Doubl e-Blinded, Placebo Controll ed, Multi-C ohort Study of the 
Safety, Pharmacokinetics , and Antiviral Activity of GS-6207 administe red subcutaneously in 
HIV-1 Infected Subjects 
GS-US-200-4072 , Amendme nt 4, 13 June 2019 
This protoc ol has been appro ved by Gilead Sciences, lnc. The following signature documents 
this approva l. 
PPD 
INVESTIGATOR STATEMENT 
I have read the proto col, including all appendices, and I agree that it contai ns all necessary 
detai ls for me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
I will provide all study personne l under my supervi sion copies of the protocol and access to all 
information provided by Gilead Sciences , Inc. I will discu ss this materia l with them to ensure 
that they are folly informed about the drugs and the study. 
Principal Investigator Name (Printed) Signature 
Date Site Num ber 
CONFIDENTIAL Page 71 13June2019 
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 72 13 June 2019Appendix 2. Study Procedures Table
Screeninga
Day 1b, h
Day 2
Day 3h
Day 4
Day 7h
Day 8
Day 9
Day 10h
Day 14
Day 29
Day 43
Day 57
Day 85h
Day 113
Day 141
Day 169h
Day 197
Day 225h
Early 
Terminationd
Written Informed 
ConsentX
Medical History X
Complete Physical 
ExaminationX X X
Symptom Directed 
Physical ExaminationX X X X X X X X X X X X X X X X X
Vital Signsj
(including weight)X X X X X X X X X X X X X X X X X X X X
12-lead ECG X X X X X X X X X
Height X
HematologyfX X X X X X X X X X X X X X X X
ChemistrygX X X X X X X X X X X X X X X X
Estimated GFRcX X X X X X X X X X X X X X X X
Urinalysis and Urine 
Chemistryk X X X X X X X X X X X X X X X X
Urine Storage Sample X X X X X X X X X X X X X X X
Serum Pregnancy TesteX X X X X X X X X X
Serum FSHiX
Urine Pregnancy test X
HBV, HCV Testing X
CD4+ Cell Count X X X X X X X X X X X X X
HIV-1 
Genotyping/Phen otypingX
HIV-1 capsid 
Genotype/Phenotyper X X
CCI
GS-6207 and TAF 
Protocol GS-US -200-4072 Final 
Gilead Science s, Inc. Amendment4 
... 
bl) ... ... = ... ... ... t'l .... ,- 0 = .,; N ... ... 
00 °' 0 ""' °' t'l ,-on ""' °' °' on i>l; · = .... t'l ,- .... .... ... ""' on 00 .... \0 .... N -
"' ;,., ;,., ;,., ;,., ;,., ;,., ;,., ;,., ;,., .... N ... = 
"' ;,., ;,., ;,., ;,., ;,., ;,., ;,., ;,., · -Q Q Q e ... Q Q Q Q Q Q Q Q Q Q Q Q "" Q Q ... en "' E--
HIV DNA genotyping X X X 
Plasma HIV-1 RNA X X X X X X X X X X X X X X X X X X X X 
Plasma Storage Sample X X X X X X X X X X X X X X X X X X X 
Inten sive PK Plasma xi Collecti on (Part A) 
Single Anytime PK X X X X X X X X X X X X X X X X Plasma Sampl e (Pait A)n 
PK Plasma Sampl e X X X X X X X X (Part B)0 ·-· ·---------- X X X X X X ••--- ---••········· 
• • • • • X 
T AF Admini stration X (PartB ) 
BIFITAF dispensation X X X X X 
Adverse Ev ents/ X X X X X X X X X X X X X X X X X X X X Concomitant Meds 
a S creening evaluations must be co mpleted within 42 days prior to Day 1. 
b Day 1 tests and procedm·e s must be compl eted prior to admin istration of the dose of s tudy drug 
c According to the Cockcroft -Gault fo1mu la 
d Wi thin 72 hom·s of pe1manently discontinuing study. Coun sel subject regarding the importance of continuing a complete ARV therapy in accordance to standard of care, and 
refer patient to an appropria te HIV treatment facility. 
e Femal es of childbe aring potential only 
f Hema tology : CBC with differenti al and platelet co unt 
g Chemi stries: Alkalin e phosphatase, AST, ALT, GGT, to tal bilimbin , direct and indirect bilimbin , total protein , albumin , LDH, C PK, bicarbon ate, BUN, calcium , chloride , 
creatinine , glucose, phosphoms, magne sium, potassium, sodium, tu-ic acid, and amyla se (reflex lipase testing if total amylase > 1.5 x ULN). 
h Fasting ovemig ht (;?: 6 hotu·s) required for Days 1, 3, 7, 10, 85, 169 and 225 
CON FIDENTIAL Page 73 13 June 2019 
GS-6207 and TAF 
Protocol GS-US -200-4072 
Gilead Science s, Inc. 
FSH te st is required for female subject s who have stopped menstruating for :C:: 12 months but do not have document ation of ovarian honuonal failure . 
J Vital signs -blood pressm·e, pulse, respirati on rate, and temperattu·e , weight Final 
Amendment4 
k Urinaly sis and Urine Chemi stry: including color & clarity , specific gravity, pH, gluco se, ketones, bilimbin , m·obilinogen , blood , nitrite, leukoc yte esterase and micro scopic 
(if micro scopic element s are seen), mine protein, albmu.in , creatinine , phosphate , calcium , magne simu and uric acid 
I 
n 
0 
p 
I r Patt A: Serial blood sample s to detenu.ine phanuacokine tics (PK) in plasma will be collected at the following time points relati ve to s tudy dmg dosing O (pre-dose), I, 2,4, 8, 
12 and 24 hom -s ost dose. 
Patt A: Smg e Anytnue PK samp e to e co ecte at t 1e Day 3, 4, an 7 t u·ou 1 225 VISlts. 
Patt B: Plasma PK-am !es to be collected at the following time points relati ve to s tudy dmg dosing: 0 (pre-dose), 0.5, I, 2, 3, 4, 6, 8, IO, 12, 24 and 48 hour s post dose; as 
well as at Days 4, 7, 8, 9 and IO at approximately the same time in the mo ming as pre-d ose on Day I. 
Patt B: PBMC PK sam es to e co ecte at e following time points relative to stlldy dmg dosing: 0 (pre-dose), I, 2, 4, 6, 8, 12, 24 and 48 hom·s post dose, as w ell as at 
Da s 4 7 8 9 and IO at a roximatel the same time in the moming as pre-dose on D ay I. 
1 1ty pnor to randomiza tion. Pait B: the capsid genotype /phenotype will be completed for 
CONFIDENTIAL Page 74 13 June 2019 
GS-6207 and TAF 
Protocol GS-US -200-4072 Final 
Gilead Sciences, Inc. Ame ndmen t 4 
Appendix 3. Management of Clinical and Laboratory Adverse Events 
Grade 1 Grade 2 
H ' .. 
May continue on t he study 
at the discretion of t he 
investigator 
CONFIDENTIAL Page 75 Grade 3 
V 
Repea t lab to co nfirm 
toxicity gra de 
V Grade 4 
If confirmed, then m onitor 
periodica lly until resolved 
or ret urned to baseline or is 
otherw i se explained 
13 June 2019 
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 76 13 June 2019Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Antiviral Toxicity Grading Scale Version: 01 April 2015
HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Hem oglobin
HIV POSITIVE
Adult and Pediatric 
57Days8.5to10.0 g/dL 
85 to 100 g/L7.5to 8.5g/dL 
75to85g/L6.5 to 7.5g/dL 
65 to 75g/L6.5g/dL
65g/L
HIV NEGATIVE
Adult and Pediatric 
57Days 10.0 to10.9 g/dL
100to109g/L
OR
Any decrease from Baseline
2.5 to 3.5g/dL
25 to 35g/L9.0 to 10.0 g/dL
90 to 100g/L
OR
Any decrease from Baseline
3.5 to 4.5g/dL
35 to 45g/L7.0 to 9.0g/dL
70 to 90g/L
OR
Any decrease from Baseline
4.5g/dL
45g/L7.0g/dL
70g/L
Infant, 36 –56 Days
(HIV POSITIVE OR
NEGATIVE )8.5 to 9.4 g/dL
85 to 94 g/L7.0 to 8.5g/dL
70 to 85g/L6.0 to 7.0 g/dL
60 to < 70 g/L6.0 g/dL
< 60 g/L
Infant, 22 –35 Days
(HIV POSITIVE OR
NEGATIVE )9.5 to 10.5 g/dL
95to 105 g/L8.0 to 9.5g/dL
80 to 95g/L7.0 to 8.0g/dL
70 to 80g/L7.0g/dL
70g/L
Infant, 1 –21 Days
(HIV POSITIVE OR
NEGATIVE )12.0 to 13.0 g/dL
120 to 130 g/L10.0 to 12.0 g/dL
100 to 120g/L9.0 to 10.0 g/dL
90 to 100g/L9.0g/dL
90g/L
Absolute Neutrophil Count 
(ANC)
Adult and Pediatric, 
≥ 7 Months#1000 to1300/mm3750to1000/mm3500to750/mm3500/mm3
1.00 to 1.30 GI/L 0.75 to 1.00 GI/L 0.50 to0.75 GI/L 0.50 GI/L
Absolute CD4+ Count
HIV NEGATIVE ONLY
Adult and Pediatric 
>13Years300to400/mm3
300to400/μL200to300/mm3
200to 300/μL100to200/mm3
100to200/μL100/mm3
100/μL
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 77 13 June 2019HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Absolute Lymphocyte Count
HIV NEGATIVE ONLY
Adult and Pediatric 
13Years600 to 650/mm3
0.60 to 0.65 GI/L500 to 600/mm3
0.50 to 0.60 GI/L350 to 500/mm3
0.35 to 0.50 GI/L350/mm3
0.35 GI/L
Platelets 100,000 to < 125,000/mm3
100to125 GI/L50,000 to 100,000/mm3
50to 100 GI/L25,000 to 50,000/mm3
25 to 50 GI/L25,000/mm3
25GI/L
WBCs 2000/mm3to 2500/mm31,500 to  2,000/mm31000 to 1,500/mm31000/mm3
2.00 GI/L to 2.50 GI/L 1.50 to 2.00 GI/L 1.00 to 1.50 GI/L 1.00 GI/L
Hypofibrinogenemia 100to200mg/dL 75 to 100mg/dL 50to 75mg/d L 50mg/d L
1.00 to2.00 g/L 0.75 to 1.00 g/L 0.50 to 0.75 g/L 0.50 g/L
Hyperfibrinogenemia ULN to 600 mg/dL 600mg/dL — —
ULN to 6.0 g/L 6.0g/L — —
Fibrin Split Product 20 to 40 μg/mL 40to 50μg/mL 50to 60μg/mL 60μg/mL
20 to 40 mg/L 40 to 50 mg/L 50 to 60 mg/L 60mg/L
Prothrombin Time (PT) 1.00 to 1.25 ULN 1.25 to 1.50 ULN 1.50 to 3.00 ULN 3.00 ULN 
International Normalized Ratio 
of prothrombin time (INR)1.1 to 1.5 x ULN >1.5 to 2.0 x ULN >2.0 to 3.0 x ULN >3.0 x ULN
Activated Partial
Thromboplastin Time (APTT) 1.00 to 1.66 ULN 1.66 to 2.33 ULN 2.33 to 3.00 ULN 3.00 ULN
Methemoglobin 5.0to10.0% 10.0 to15.0% 15.0 to20.0% 20.0% 
# Anoverlap between the Grade 1 scale and the Lab’s normal range for absolute neutrophils may result for pediatric subjects. Please follow the Gilead convention of grading 
any resu lt within the LLN and ULN a 0.
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 78 13 June 2019CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyponatremia 130 to <LLN mEq/L 125 to 130mEq/L 121 to 125mEq/L 121 mEq/L
130 to <LLN mmol/L 125 to 130mmol/L 121 to 125mmol/L 121 mmol/L
Hypernatremia >ULN to 150 mEq/L 150 to 154 mEq/L 154 to 159 mEq/L 159 mEq/L
>ULN to 150 mmol/L 150 to 154 mmol/L 154 to 159 mmol/L 159 mmol/L
Hypokalemia 
Adult and Pediatric
1 Year3.0 to <LLN mEq/L 2.5 to 3.0mEq/L 2.0 to 2.5mEq/L 2.0 mEq/L
3.0 to <LLN mmol/L 2.5 to 3.0mmol/L 2.0 to 2.5mmol/L 2.0 mmol/L
Infant <1 Year 3.0 to 3.4 mEq/L
3.0 to 3.4 mmol/L2.5 to 3.0mEq/L
2.5 to <3.0 mmolL2.0 to 2.5mEq/L
2.0 to <2.5 mmolL2.0 mEq/L
<2.0 mmolL
Hyperkalemia 
Adult and Pediatric
1 Year5.6 to 6.0 mEq/L
5.6 to 6.0 mmol/L6.0 to 6.5 mEq/L
6.0 to 6.5 mmol /L6.5 to 7.0 mEq/L
6.5 to 7.0 mmol/L7.0 mEq/L
7.0 mmol/L
Infant <1 Year >ULN to 6.0 mEq/L
>ULN to 6.0 mmol/L> 6.0 to 6.5 mEq/L
> 6.0 to 6.5 mmol/L6.5 to 7.0 mEq/L
6.5 to 7.0 mmol/L7.0 mEq/L
7.0 mmol/L
Hypoglycemia
Adult and Pediatric
1Month55 to 64 mg/dL
3.03 to 3.58 mmol/L40 to 55mg/d L
2.20 to 3.03 mmol/L30 to 40mg/d L
1.64 to 2.20 mmol/L30 mg/dL
1.64 mmol/L
Infant, 1Month 50 to 54 mg/dL
2.8 to 3.0 mmol/L40 to 50mg/d L
2.2 to 2.8mmol/L30 to 40mg/d L
1.7 to 2.2mmol/L30 mg/dL
1.7 mmol/L
Hyperglycemia, Nonfasting 116to 160 mg/dL 160 to 250 mg/dL 250 to 500 mg/dL 500 mg/dL
6.42 to 8.91 mmol/L 8.91 to 13.90 mmol/L 13.90 to 27.79 mmol/L 27.79 mmol/L
Hyperglycemia, Fasting 110 to 125 mg/dL
6.08 to 6.96 mmol/L>125 to 250 mg/dL
>6.96 to 13.90 mmol/L>250 to 500 mg/dL
>13.90 to 27.79 mmol/L>500 mg/dL
>27.79 mmol/L
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 79 13 June 2019CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hypocalcemia 
(corrected for albumin if 
appropriate*)
Adult and Pediatric
2 Years7.8 <LLN mg/dL
1.94 to <LLN mmol/L7.0 to 7.8 mg/dL
1.74 to 1.94 mmol/L6.1 to 7.0mg/dL
1.51 to 1.74 mmol/L6.1mg/d L
1.51 mmol/L
Pediatric ≥7 days -2 Years 7.8 to 8.4 mg/dL
1.94 to 2.10 mmol/L7.0 to <7.8 mg/dL
1.74 to <1.94 mmolL6.1 to <7.0 mg/dL
1.51 to < 1.74 mmolL< 6.1 mg/d L
< 1.51 mmol/L
Infant, 7Days 6.5 to 7.5 mg/dL
1.61 to 1.88 mmol/L6.0 to 6.5 mg/dL
1.49 to < 1.61 mmol/L5.5 to 6.0 mg/dL
1.36 to < 1.49 mmol/L 5.5 mg/dL
< 1.36 mmol/L
Hypercalcemia (corrected 
for albumin if appropriate*)
Adult and Pediatric 
7Days>ULN to 11.5 mg/dL 11.5 to 12.5 mg/dL 12.5 to 13.5 mg/dL 13.5 mg/dL
>ULN to 2.88 mmol/L 2.88 to 3.13 mmol/L 3.13 to 3.38 mmol/L 3.38 mmol/L
Infant, 7Days 11.5 to 12.4 mg/dL
2.86 to 3.10 mmol/L12.4 to 12.9 mg/dL
> 3.10 to 3.23 mmol/L12.9 to 13.5 mg/dL
> 3.23 to 3.38 mmol/L13.5 mg/dL
> 3.38 mmol/L
Hypocalcemia (ionized) 3.0 mg/dL to LLN 2.5 to < 3.0 mg/dL 2.0 to 2.5 mg/dL 2.0 mg/dL
0.74 mmol/L to LLN 0.62 to 0.74 mmol/L 0.49 to0.62 mmol/L 0.49 mmol/L
Hypercalcemia (ionized) ULN to 6.0 mg/dL 6.0 to 6.5 mg/dL 6.5 to 7.0 mg/dL 7.0 mg/dL
ULN to 1.50 mmol/L 1.50 to 1.63 mmol/L 1.63 to 1.75 mmol/L 1.75 mmol/L
Hypomagnesemia 1.40 to <LLN mg/dL
1.2 to <LLN mEq /L1.04 to 1.40 mg/dL
0.9 to 1.2 mEq/L0.67 to 1.04 mg/dL
0.6 to 0.9 mEq/L0.67 mg/dL
0.6 mEq/L
0.58 to <LLN mmol/L 0.43 to 0.58 mmol/L 0.28 to 0.43 mmol/L 0.28 mmol/L
Hypophosphatemia
Adult and Pediatric
14Years2.0 to < LLN mg/dL
0.63 to LLN mmol/L1.5 to 2.0 mg/dL
0.47 to 0.63 mmol/L1.0 to 1.5 mg/dL
0.31 to 0.47 mmol/L1.0 mg/dL
0.31 mmol/L
Pediatric 1 Year– 14 Years 3.0 to <LLN mg/dL
0.96 to <LLN mmol/L2.5 to 3.0 mg/dL
0.80 to < 0.96 mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 80 13 June 2019CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Pediatric 1Year 3.5 to <LLN mg/dL
1.12 to <LLN mmol/L2.5 to 3.5mg/dL
0.80 to < 1.12 mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
Hyperbilirubinemia 
Adult and Pediatric 
>14Days1.0 to 1.5 ULN 1.5 to 2.5 ULN 2.5 to 5.0 ULN 5.0 ULN 
Infant, 14Days
(non-hemolytic)NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 to 30.0 mg/dL
> 428 to 513 μmol/L30.0 mg/dL
> 513 μmol/L
Infant, 14Days
(hemolytic)NA NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 mg/dL
> 428 μmol/L
Blood Urea Nitrogen 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Hyperuricemia >ULN to 10.0 mg/dL 10.0 to 12.0 mg/dL 12.0 to 15.0 mg/dL 15.0 mg/dL
>ULN to 597 μmol/L 597 to 716 μmol/L 716 to 895 μmol/L 895 μmol/L
Hypouricemia
Adult and Pediatric
≥ 1 year
Infant < 1 Year1.5 mg/dL to LLN
87 μmol/L to LLN1.0 to 1.5 mg/dL
57 to 87 μmol/L0.5 to 1.0 mg/dL
27 to 57 μmol/L0.5 mg/dL
27 μmol/L
N/A 1.0 mg/dl to <LLN -
57 μmol to <LLN0.5 to 1.0 mg/dL
27 to 57 μmol/L0.5 mg/dL
27 μmol/L
Creatinine** 1.50 to 2.00 mg/dL
133 to 177 μmol/L2.00 to 3.00 mg/dL
177 to 265 μmol/L3.00 to 6.00 mg/dL 
265 to 530 μmol/L6.00 mg/dL
530 μmol/L
Bicarbonate
Adult and Pediatric 
≥ 4 Years16.0 mEq/L to LLN 11.0 to 16.0 mEq/L 8.0 to 11.0 mEq/L 8.0 mEq/L
16.0 mmol/L to LLN 11.0 to 16.0 mmol/L 8.0 to 11.0 mmol/L 8.0 mmol/L
Pediatric < 4 Years NA 11.0 mEq/Lto <LLN 8.0 to 11.0 mEq/L 8.0 mEq/L
11.0 mmol/L to <LLN 8.0 to 11.0 mmol/L 8.0 mmol/L
Triglycerides
(Fasting)NA 500 to 750 mg/dL
5.64–8.47 mmol/L750 to 1200 mg/dL
8.47–13.55 mmol/L1200 mg/ dL
13.55 mmol/L
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 81 13 June 2019CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
LDL (Fasting)
Adult130 to 160 mg/dL >160 to 190 mg/dL > 190 mg/dL NA
3.35 to 4.15 mmol/L >4.15 to 4.92 mmol/L >4.92 mmol/L
LDL (Fasting)
Pediatric >2 to <18 years110 to 130 mg/dL >130 to 190 mg/dL > 190 mg/dL NA
2.84 to 3.37 mmol /L >3.37 to 4.92 mmol/L >4.92 mmol/L
Hypercholesterolemia
(Fasting)200 to 239 mg/dL 239 to 300 mg/dL 300 mg/dL NA
5.16 to 6.19 mmol/L 6.19 to 7.77 mmol/L 7.77 mmol/L
Pediatric 18 Years 170 to 199 mg/dL
4.39 to 5.15 mmol/L199 to 300 mg/ dL
5.15 to 7.77 mmol/L300 mg/dL
7.77 mmol/LNA
Creatine Kinase 3.0 to 6.0 ULN 6.0 to 10.0 ULN 10.0 to 20.0 ULN 20.0 ULN
* Calcium should be corrected for albumin if albumin is < 4.0 g/dL
** An overlap between the Grade 1 scale and the Lab’s normal range for creatinine may res ult for Male subjects >70 yrs. Please follow the Gilead convention of grading any 
result within the LLN a nd ULN a 0.
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 82 13 June 2019ENZYMES
Grade 1 Grade 2 Grade 3 Grade 4
AST (SGOT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
ALT (SGPT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
GGT 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Alkaline Phosphatase 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Total Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Pancreatic Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Lipase 1.0 to 1.5 ULN 1.5 to 3.0 ULN 3.0 to 5.0 ULN 5.0 ULN
Albumin
Pediatrics <16 years 
≥ 16 years- 2.0 to LLN g/dL
20 to LLN g/L2.0 g/dL
20 g/LNA
3.0 g/dL to LLN
30 g/L to LLN2.0 to 3.0 g/dL
20 to 30 g/L2.0 g/dL
20 g/LNA
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 83 13 June 2019URINALYSIS
Grade 1 Grade 2 Grade 3 Grade 4
Hem aturia (Dipstick) 1 2 3-4+ NA
Hem aturia (Quantitative) 
See Note below
Females >ULN -10RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
Males 6-10 RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
Proteinuria (Dipstick) 1 2–3 4 NA
Proteinuria, 24 Hour Collection
Adult and Pediatric 
10 Years200 to999 mg/24 h >999 to 1999 mg/24 h >1999 to3500 mg/24 h 3500 mg/24 h
Pediatric 3 Mo to 
<10Years201 to499 mg/m2/24h >499 to799 mg/m2/24 h >799 to1000 mg/m2/24 h 1000 mg/ m2/24 h
Glycosuria (Dipstick) 1+ 2-3 4 NA
Notes:
 Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by Covance Laboratory, however for other laboratorie s, toxicity grades will only be assigned to 
Dipstick Hematuria.
 With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be assigne d Grade 0.
 If the severity of a clinical AE could fall under either one of two grades (eg, ., the se verity of an AE could be either Grade 2 or Grade 3 ), select the higher of the two grades for 
the AE.
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 84 13 June 2019CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Cardiac Arrhythmia (general)
(By ECG or physical exam)Asymptomatic AND No 
intervention indicatedAsymptomatic AND 
Non-urgent medical 
intervention indicatedSymptomatic, 
non-life-threatening AND 
Non-urgent medical 
intervention indicated Life-threatening arrhythmia 
OR Urgent intervention 
indicated
Cardiac- ischemia/Infarction NA NA Symptomatic ischemia 
(stable angina) OR Testing 
consistent with ischemia Unstable angina OR Acute 
myocardial infarction
Hem orrhage (significant acute 
blood loss)NA Symptomatic AND No 
transfusion indicatedSymptomatic AND 
Transfusion of 2units 
packed RBCs (for children 
10cc/kg) indicated Life-threatening hypotension 
OR Transfusion of 2units 
packed RBCs indicated (for 
children 10cc/kg) indicated
Hypertension (with repeat 
testing at same visit)140– 159mmH g systolic 
OR 
90–99 mmHg diastolic159–179 mmHg systolic 
OR 
99–109 mmHg diastolic179mmHg systolic 
OR 
109mmHg diastolicLife-threatening consequences 
(eg, malignant hypertension) 
OR Hospitalization (other than 
ER visit) indicated
Pediatric 17Years (with 
repeat testing at same visit)NA 91st–94th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)≥95th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)Life-threatening consequences 
(eg, malignant hypertens ion) 
OR Hospitalization indicated 
(other than emergency room 
visit)
Hypotension NA Symptomatic, corrected w ith 
oral fluid replacementSymptomatic, IV fluids 
indicatedShock requiring use of 
vasopressors or mechanical 
assistance to maintain blood 
pressure
Pericardial Effusion Asymptomatic, small 
effusion requiring no 
interventionAsymptomatic, moderate or 
larger effusion requiring no 
interventionEffusion with non -life-
threatening physiologic 
consequences OR Effusion 
with nonurgent intervention 
indicatedLife-threatening consequences 
(eg, tamponade) OR Urgent 
intervention indicated
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 85 13 June 2019CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Prolonged PR Interval PR interval 
0.21 to 0.25 secPR interval
0.25 secType II 2nd degree AV 
block OR Ventricular pause 
3.0 secCom plete AV block 
Pediatric 16 Years 1st degree AV block
(PR > normal for age and 
rate)Type I 2nd degree AV block Type II 2nd degree AV 
block Com plete AV block
Prolonged QTc Asymptomatic, QTc interval 
0.45 to 0.47 sec OR Increase 
interval 0.03 sec above 
baselineAsymptomatic, QTc interval 
0.48 to 0.49 sec OR Increase 
in interval 0.03 to 0.05 sec 
above baselineAsymptomatic, QTc interval 
0.50 sec OR Increase in 
interval 0.06 sec above 
baselineLife-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ven tricular 
dysrhythmia
Pediatric 16Years Asymptomatic, QTc interval 
0.450 to 0.464 sec Asymptomatic, QTc interval 
0.465 to 0.479 sec Asymptomatic, QTc interval 
0.480 sec Life-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Thrombosis/Embolism NA Deep vein thrombosis AND 
No intervention indicated 
(eg, anticoagulation, lysis 
filter, invasive procedure) Deep vein thrombosis AND 
Intervention indicated 
(eg,anticoagulation, lysis
filter, invasive procedure) Embolic event (eg, pulmonary 
embolism, life -threatening 
thrombus) 
Vasovagal Episode (associated 
with a procedure of any kind)Present without loss of 
consciousness Present with transient loss of 
consciousnessNA NA
Ventricular Dysfunction 
(congestive heart failure, 
CHF)NA Asymptomatic diagnostic 
finding AND intervention 
indicatedNew  onset with symptoms 
OR Worsening symptomatic 
CHFLife-threatening CHF
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 86 13 June 2019RESPIRATORY
Grade 1 Grade 2 Grade 3 Grade 4
Bronchospasm (acute) FEV1 or peak flow  reduced to 
70% to 80%FEV1 or peak flow  50% to 69% FEV1 or peak flow  25% 
to49% Cyanosis OR FEV1 or peak flow  
25% OR Intubation
Dyspnea or Respiratory 
DistressDyspnea on exertion with no 
or minimal interference with 
usual social & functional 
activities Dyspnea on exertion causing 
greater than minimal 
interference with usual social & 
functional activities Dyspnea at rest causing 
inability to perform usual 
socia l & functional 
activities Respiratory failure with 
ventilatory support indicated
Pediatric 14 Years Wheezing OR minimal 
increase in respiratory rate for 
ageNasal flaring OR Intercostal 
retractions OR Pulse oximetry 
90% to 95%Dyspnea at rest causing 
inability to perform usual 
social & functional 
activities OR Pulse 
oximetry 90%Respiratory failure with 
ventilatory support indicated
OCULAR/VISUAL
Grade 1 Grade 2 Grade 3 Grade 4
Uveitis Asymptomatic but detectable 
on examSymptomatic anterior uveitis OR 
Medical intervention indicatedPosterior or pan -uveitis OR 
Operative intervention 
indicatedDisabling visual loss in affected 
eye(s) 
Visual Changes (from 
baseline)Visual changes causing no or 
minimal interference with 
usual social & functional 
activitiesVisual changes causing greater 
than minimal interference with 
usual social & functional 
activitiesVisual changes causing 
inability to perform usual 
social & functional 
activitiesDisabling visual loss in affected 
eye(s)
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 87 13 June 2019SKIN
Grade 1 Grade 2 Grade 3 Grade 4
Alopecia Thinning detectable by 
study participant or 
caregiver (for disabled 
adults)Thinning or patchy hair loss 
detectable by health care 
providerCom plete hair loss NA
Cutaneous Reaction –Rash Localized macular rash Diffuse macular, 
maculopapular, or 
morbilliform rash OR Target 
lesions Diffuse macular, 
maculopapular, or morbilliform 
rash with vesicles or limited 
number of bullae OR 
Superficial ulcerations of 
mucous membrane limited to 
one siteExtensive or generalized 
bullous lesions OR 
Stevens -Johnson syndrome 
OR Ulceration of mucous 
membrane involving 
twoor more distinct 
mucosal sites OR Toxic 
epidermal necrolysis 
(TEN)
Hyperpigmentation Slight or localized Marked or generalized NA NA
Hypopigmentation Slight or localized Marked or generalized NA NA
Pruritis (itching –no skin 
lesions) 
(See also Injection Site 
Reactions: Pruritis associated 
with injection)Itching causing no or 
minimal interference with 
usual social & functional 
activitiesItching causing greater than 
minimal interference with 
usual social & functional 
activitiesItching causing inability to 
perform usual social & 
functional activities NA
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 88 13 June 2019GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Anorexia Loss of appetite w ithout 
decreased oral intakeLoss of appetite associated with 
decreased oral intake without 
significant weight loss Loss of appetite associated 
with significant weight loss Life-threatening 
consequences OR Aggressive 
intervention indicated 
[eg,tube feeding or total 
parenteral nutrition]
Ascites Asymptomatic Symptomatic AND Intervention 
indicated (eg, diuretics or 
therapeutic paracentesis)Symptomatic despite 
interventionLife-threatening 
consequences
Cholecystitis NA Symptomatic AND Medical 
intervention indicatedRadiologic, endoscopic, or 
operative intervention 
indicatedLife-threatening 
consequences (eg, sepsis or 
perforation) 
Constipation NA Persistent constipation requiring 
regular use of dietary 
modifications, laxatives, or 
enemas Obstipation with manual 
evacuation indicatedLife-threatening 
consequences 
(eg,obstruction)
Diarrhea 
Adult and Pediatric 
1YearTransient or intermittent 
episodes of unformed 
stools OR Increase of 
3stools over 
baseline/24 hrPersistent episodes of unformed 
to watery stools OR Increase of 
4–6 stools over baseline per 
24hrs. Bloody diarrhea OR Increase 
of 7stools per 24 -hour 
period OR IV fluid 
replacement indicatedLife-threatening 
consequences 
(eg,hypotensive shock)
Pediatric 1Year Liquid stools (more 
unformed than usual) but 
usual number of stoolsLiquid stools with increased 
number of stools OR Mild 
dehydrationLiquid stools with moderate 
dehydrationLiquid stools resulting in 
severe dehydration with 
aggressive rehydration 
indicated OR Hypotensive 
shock
Dysphagia -Odynophagia Symptomatic but able to 
eat usual dietSymptoms causing altered 
dietary intake without medical 
intervention indicatedSymptoms causing severely 
altered dietary intake with 
medical intervention 
indicatedLife-threatening reduction in 
oral intake
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 89 13 June 2019GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Mucositis/Stomatitis 
(clinical exam)
See also Proctitis, 
Dysphagia -OdynophagiaErythema of the mucosa Patchy pseudomembranes or 
ulcerations Confluent pseudomembranes
or ulcerations OR Mucosal 
bleeding with minor traumaTissue necrosis OR Diffuse 
spontaneous mucosal 
bleeding OR Life -threatening 
consequences (eg, aspiration, 
choking)
Nausea Transient ( 24hours) or 
intermittent nausea with no 
or minimal interference 
with oral intakePersistent nausea resulting in 
decreased oral intake for 
24-48hoursPersistent nausea resulting in 
minimal oral intake for 
48hours OR Aggressive 
rehydration indicated 
(eg,IVfluids)Life-threatening 
consequences 
(eg,hypotensive shock )
Pancreatitis NA Symptomatic AND 
Hospitalization not indicated 
(other than ER visit)Symptomatic AND 
Hospitalization indicated 
(other than ER visit)Life-threatening 
consequences (eg, sepsis, 
circulatory failure, 
hemorrhage)
Proctitis 
(functional -symptomatic)
Also see Mucositis/ 
Stomatitis for Clinical ExamRectal discomfort AND No 
intervention indicatedSymptoms causing greater than 
minimal interference with usual 
social & functional activities 
OR Medical intervention 
indicated Symptoms causing inability 
to perform usual social/ 
functional activities OR 
Operative intervention 
indicated Life-threatening 
consequences 
(eg,perforation)
Vom iting Transient or intermittent 
vomiting with no or 
minimal interference with 
oral intakeFrequent episodes of vomiting 
with no or mild dehydrationPersistent vomiting resulting 
in orthostatic hypotension OR 
Aggressive rehydration 
indicatedLife-threatening 
consequences 
(eg,hypotensive shock)
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 90 13 June 2019NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Alteration in 
Personality -Behavior or in 
Mood (eg, agitation, 
anxiety, depression, mania, 
psychosis)Alteration causing no or 
minimal interference with 
usual social & functional 
activities Alteration causing greater than 
minimal interference with 
usual so cial & functional 
activities Alteration causing inability to 
perform usual social & 
functional activities Behavior potentially harmful 
to self or others 
(eg,suicidal/homicidal 
ideation or attempt, acute 
psychosis) OR Causing 
inability to perform basic 
self-care functions
Altered Mental Status 
For Dementia, see Cognitive 
and Behavioral/Attentional 
Disturbance (including 
dementia and ADD)Changes causing no or 
minimal interference with 
usual social & functional 
activitiesMild lethargy or somnolence 
causing greater than minimal 
interference with usual social 
& functional activitiesConfusion, memory 
impairm ent, lethargy, or 
somnolence causing inability 
to perform usual social & 
functional activitiesDelirium OR obtundation, OR 
coma
Ataxia Asymptomatic ataxia 
detectable on exam OR 
Minimal ataxia causing no 
or minimal interference with 
usual social & functional 
activitiesSymptomatic ataxia causing 
greater than minimal 
interference with usual social 
& functional activitiesSymptomatic ataxia causing 
inability to perform usual 
social & functional activities Disabling ataxia causing 
inability to perform basic 
self-care functions
Cognitive and 
Behavioral/Attentional 
Disturbance (including 
dementia and Attention 
Deficit Disorder) Disability cau sing no or 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources not indicatedDisability causing greater than 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources on part -time basis 
indicatedDisability causing inability to 
perform usual social & 
functional activities OR 
Specialized resources on a 
full-time basis indicatedDisability causing inability to 
perform basic self -care 
functions OR 
Institutionalization indicated
CNS Ischemia
(acute)NA NA Transient ischemic attack Cerebral vascular accident 
(CVA, stroke) with 
neurological deficit 
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 91 13 June 2019NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Developmental delay –
Pediatric 16 YearsMild developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate 
for the setting Moderate developmental 
delay, either motor or 
cognitive, as determined by 
comparison with a 
developmental screening tool 
appropriate for the setting Severe developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate for 
the setting Developmental regression, 
either motor or cognitive, as 
determined b y comparison 
with a developmental 
screening tool appropriate for 
the setting
Headache Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference with 
usual social & functional 
activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesSymptoms causing inability to 
perform basic self -care 
functions OR Hospitalization 
indicated (other than ER visit) 
OR Headache with significant 
impairm ent of alertness or
other neurologic function 
Insomnia NA Difficulty sleeping causing 
greater than minimal 
interference with usual 
social/functional activitiesDifficulty sleeping causing 
inability to perform usual 
social & functional activitiesDisabling insomnia causing 
inability to perform basic 
self-care functions
Neuromuscular Weakness 
(including myopathy & 
neuropathy) Asymptomatic with 
decreased strength on exam 
OR Minimal muscle 
weak -ness causing no or 
minimal interference with 
usual social & functional 
activitiesMuscle weakness causing 
greater than minimal 
interference with usual social 
& functional activitiesMuscle weakness causing 
inability to perform usual 
social & functional activities Disabling muscle weakness 
causing inability to perform 
basic self -care f unctions OR 
Respiratory muscle weakness 
impairing ventilation
Neurosensory Alteration 
(including paresthesia and 
painful neuropathy)Asymptomatic with sensory 
alteration on exam or 
minimal paresthesia causing 
no or minimal interference 
with usual social &
functional activities Sensory alteration or 
paresthesia causing greater 
than minimal interference with 
usual social & functional 
activities Sensory alteration or 
paresthesia causing inability to 
perform usual social & 
functional activitiesDisabling sen sory alteration or 
paresthesia causing inability to 
perform basic self -care 
functions
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 92 13 June 2019NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Seizure: (new onset) NA 1 seizure 2–4 seizures Seizures of any kind that are 
prolonged, repetitive 
(eg,status epilepticus), or 
difficult to control 
(eg,refractory epilepsy)
Seizure: (pre- existing) 
For Worsening of Existing 
Epilepsy the Grades Should 
Be Based on an Increase 
from Previous Level of 
Control to Any of These 
LevelsNA Increased frequency of 
pre-existing seizures 
(non-repetitive) without 
change in seizure character 
OR infrequent breakthrough 
seizures while on stable meds 
in a previously controlled 
seizure disorderChange in seizure character 
from baseline either in 
duration or quality 
(eg,severity or focality) Seizures of any kind that are 
prolong ed, repetitive 
(eg,status epilepticus), or 
difficult to control 
(eg,refractory epilepsy)
Seizure 
–Pediatric 18 YearsSeizure, generalized onset 
with or without secondary 
generalization, lasting 
< 5minutes with < 24hours 
post ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 
5-20minutes with 
< 24 hours post ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 
> 20 minutes Seizure, generalized onset 
with or without secondary 
generalization, requiring 
intubation and sedation
Syncope (not associated 
with a procedure)NA Present NA NA
Vertigo Vertigo causing no or 
minimal interference with 
usual social & functional 
activitiesVertigo causing greater than 
minimal interference with 
usual social & functional 
activities Vertigo causing inability to 
perform usual social & 
functional activitiesDisabling vertigo causing 
inability to perform basic 
self-care functions
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 93 13 June 2019MUSCULOSKELETAL
Grade 1 Grade 2 Grade 3 Grade 4
Arthralgia
See also ArthritisJoint pain causing no or 
minimal interference with 
usual social & functional 
activitiesJoint pain causing greater than 
minimal interference with usual 
social & functional activitiesJoint pain causing inability 
to perform usual social & 
functional activitiesDisabling joint pain causing 
inability to perform basic 
self-care functions
Arthritis
See also ArthralgiaStiffness or joint sw elling 
causing no or minimal 
interference with usual 
social & functional 
activitiesStiffness or joint sw elling causing 
greater than minimal interference 
with usual social & functional 
activitiesStiffness or joint sw elling 
causing inability to perform 
usual social & functional 
activi tiesDisabling joint stiffness or 
swelling causing inability to 
perform basic self -care 
functions
Bone Mineral Loss BMD t -score or z- score
–2.5 to –1.0 BMD t -score or z- score –2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Pediatric 21Years BMD z -score 
–2.5 to –1.0BMD z -score < –2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Myalgia
(non-injection site)Muscle pain causing no or 
minimal interference with 
usual social & functional 
activitiesMuscle pain causing greater than 
minimal interference with usual 
social & functional activitiesMuscle pain causing 
inability to perform usual 
social & functional 
activitiesDisabling muscle pain causing 
inability to perform basic 
self-care functions
Osteonecrosis NA Asymptomatic with radiographic 
findings AND No operative 
intervention indicatedSymptomatic bone pain 
with radiographic findings 
OR Operative intervention 
indicatedDisabling bone pain with 
radiographic findings causing 
inability to perform basic 
self-care functions
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 94 13 June 2019SYSTEMIC
Grade 1 Grade 2 Grade 3 Grade 4
Acute Systemic Allergic 
Reaction Localized urticaria
(wheals) with no medical 
intervention indicatedLocalized urticaria with medical 
intervention indicated OR Mild 
angioedema with no medical 
intervention indicatedGeneralized urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild 
bronchospasmAcute anaphylaxis OR 
Life-threatening 
bronchospasm OR laryngeal 
edema
Chills Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activities Symptoms causing inability to 
perform usual social & 
functional activitiesNA
Fatigue
MalaiseSymptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesIncapacitating fatigue/malaise 
symptoms causing inability to 
perform basic self -care 
functions
Fever (nonaxillary) 37.7C to 38.6 C
99.8Fto 101.5 F38.7C to 39.3 C
101.6 F to 102.8 F39.4C to 40.5 C
102.9 F to 104.9 F40.5C 
104.9 F
Pain-Indicate Body Site
See also Injection Site 
Pain, Headache, 
Arthralgia, and MyalgiaPain causing no or 
minimal interference with 
usual social & functional 
activitiesPain causing greater than minimal 
interference with usual social & 
functional activitiesPain causing inability to 
perform usual social & 
functional activitiesDisabling pain causing 
inability to perform basic 
self-care functions OR 
Hospitalization (other than ER 
visit) indicated
Unintentional Weight 
LossNA 5% to 9% loss in body weight from 
baseline10% to 19% loss in body 
weight from baseline20% loss i n body weight 
from baseline OR Aggressive 
intervention indicated 
[eg, tube feed ing or total 
parenteral nutrition]
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 95 13 June 2019INJECTION SITE REACTION
Grade 1 Grade 2 Grade 3 Grade 4
Injection Site Pain (pain 
without touching)
Or Tenderness (pain when 
area is touched) Pain/tenderness causing no 
or minimal limitation of use 
of limbPain/tenderness limiting use of 
limb OR Pain/tenderness 
causing greater than minimal 
interference with usual social 
& functional activitiesPain/tenderness causing 
inability to perform usual 
social & functional 
activitiesPain/tenderness causing inability 
to perform basic self -care 
function OR Hospitalization 
(other than ER visit) indicated 
for management of 
pain/tenderness
Injection Site Reaction 
(Localized), 15YearsErythema OR Induration
of 55cm to 9 9cm 
(or2581 cm2)Erythema OR Induration OR 
Edema 9cm any diameter 
(or 81cm2)Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR DrainageNecrosis (involving dermis and 
deeper tissue)
Pediatric 15Years Erythem a OR Induration 
OR Edema present but 
2.5cm diameterErythem a OR Induration 
OR Edema > 2.5cm 
diameter but < 50% surface 
area of the extrem ity 
segment (eg, upper 
arm/thigh)Erythem a OR Induration 
OR Edema involving 
50% surface area of the 
extremity segment 
(eg,upper arm /thigh) OR 
Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR 
DrainageNecrosis (involving dermis and 
deeper tissue)
Pruritis Associated with 
Injection 
See also Skin: Pruritis 
(itching —no skin lesions)Itching localized to injection 
site AND Relieved 
spontaneously or w ith 
48h treatment Itching beyond the injection 
site but not generalized OR 
Itching localized to injection 
site requiring 48h treatment Generalized itching causing 
inability to perfo rm usual 
social & functional 
activitiesNA
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 96 13 June 2019ENDOCRINE/METABOLIC
Grade 1 Grade 2 Grade 3 Grade 4
Lipodystrophy (eg, back 
of neck, breasts, 
abdomen)Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)Detectable on physical exam by 
health care providerDisfiguring OR Obvious 
changes on casual visual 
inspectionNA
Diabetes Mellitus NA New  onset without need to initiate 
medication OR Modification of 
current meds to regain glucose 
controlNew  onset with initiation of 
indicated med OR Diabetes 
uncontrolled despite treatment 
modificationLife-threatening consequences 
(eg, ketoacidosis, 
hyperosmolar non -ketotic 
coma) 
Gynecomastia Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)Detectable on physical exam by 
health care providerDisfiguring OR Obvious on 
casual visual inspectionNA
Hyperthyroidism Asymptomatic Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid suppression therapy 
indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despite treatment 
modification Life-threatening consequences 
(eg, thyroid storm)
Hypothyroidism Asymptomatic Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid replacement therapy 
indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despite treatment 
modification Life-threatening consequences
(eg, myxedema coma)
Lipoatrophy (eg, fat loss 
from the face, extremities, 
buttocks)Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)Detectable on physical exam by 
health care providerDisfiguring OR Obvious on 
casual visual inspectionNA
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 97 13 June 2019GENITOURINARY
Grade 1 Grade 2 Grade 3 Grade 4
Intermenstrual Bleeding 
(IMB)Spotting observed by participant 
OR Minimal blood observed 
during clinical or colposcopic 
examIntermenstrual bleeding not 
greater in duration or amount 
than usual menstrual cycleIntermenstrual bleeding greater 
in duration or amount than usual 
menstrual cycleHem orrhage with 
life-threatening hypotension 
OR Operative intervention 
indicated
Urinary Tract 
obstruction (eg, stone)NA Signs or symptoms of urinary 
tract obstruction without 
hydronephrosis or renal 
dysfunctionSigns or symptoms of urinary 
tract obstruction with 
hydronephrosis or renal 
dysfunctionObstruction causing 
life-threatening 
consequences
INFECTION
Grade 1 Grade 2 Grade 3 Grade 4
Infection (any other 
than HIV infection)Localized, no systemic antiμbial 
treatment indicated AND 
Symptoms causing no or 
minimal interference with usual 
social & functional activitiesSystemic antiμbial treatment 
indicated OR Symptoms 
causing greater than minimal 
interference with usual social 
& functional activitiesSystemic antiμbial treatment 
indicated AND Symptoms 
causing inability to perform 
usual social & functional 
activities OR Operative 
interven tion (other than simple 
incision and drainage) indicatedLife-threatening 
consequences (eg, septic 
shock)
Basic Self-care Functions: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.
Usual Social & Functional Activities: Adaptive tasks and desirable activities, such as going to work, shopping, cooking, use of transp ortation, pursuing a hobby, etc
GS-6207 and TAF
Protocol GS -US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 98 13 June 2019Appendix 5. Definitions of Stage 3 Oppo rtunistic Illnesses in HIV 
(CDC Guidelines)
1) Candidiasis of bronchi, trachea, or lungs
2)Candidiasis of esophagus
3)Cervical cancer, invasive
4)Coccidioidomy cosis, disseminated or extrapulmonary
5)Cryptococcosis, extrapulmonary
6)Cryptosporidiosis, chronic intestinal ( 1month duration)
7)Cytomegalo virus disease (other than liver, spleen or nodes)
8)Cytomegalovirus retinitis (with loss of vision)
9)Encephalopath y, HIV-related
10) Herpes simplex: chronic ulcer(s) ( 1month duration); or bronchitis, pneumonitis or 
esophagitis
11)Histoplasmosis, disseminated or e xtrapulmonary
12)Isosporiasis, chronic intestinal ( 1month duration)
13)Kaposi’s sarcoma
14)Lym phoma, Burkitt’s (or equivalent term)
15)Lym phoma, immunoblastic (or equivalent term)
16)Lym phoma, primary , of brain
17)Mycobacterium avium complex or Myobacterium kansasii , disseminated or extrapulmonary
18)Mycobacterium tuberculosis , of any  site, pulmonary , disseminated or extrapulmonary
19)Mycobacterium , other species or unidentified species, disseminated or extrapulmonary
20)Pneumocy stis jirovecii (previously  known as “ Pneumocystis carinii) pneumonia
21)Pneumonia, recurrent
22) Progressive multifocal leukoencephalopathy
23)Salmonella septicemia, recurrent
24)Toxoplasmosis of brain
25)Wasting sy ndrome attributed to HIV infection
CDC Stage -3-Defining Opportunistic I llnesses in HIV Infection - 2014 { Schneider 2008}
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 99 13 June 2019Appendix 6. GS- 6207 Pregnancy Precautions (Part A) , Definition for Female of 
Childbearing Potential, and Contrace ptive Requirements
1)Definitions
a.Definition of Childbearing Potential
For the purposes of this study , a female born subject is considered of childbearing potential 
following the initiation of pubert y (Tanner stage 2) until becoming post -menopausal, unless 
permanentl y sterile or with medical ly documented ovarian failure.
Women are considered to be in a postmenopausal state when they  are > 54 years of age with 
cessation of previously  occurring menses for > 12 months without an alternative cause. In 
addition, wo men of an y age with amenorrhea of >12 months may  also be considered 
postmenopausal if their follicle stimulating hormone (FSH) level is in the postmenopausal range 
and they  are not using hormonal contraception or hormonal replacement therapy .
Permanent st erilization includes hy sterectomy , bilateral oophorectom y, or bilateral 
salpingectomy  in a female subject of an y age.
b.Definition of Male Fertility
For the purposes of this study , a male born subject is considered fertile after the initiation of 
puberty  unless permanently  sterile b y bilateral orchidectomy or medical documentation.
2)Contraception Requirements for Female Subjects
a.Study Drug Effects on Pregnancy and Hormonal Contraception
GS-6207 is contraindicated in pregnancy  as a malformation effect has been 
demonstrated/suspected or is unknown, taking into consideration class effects, genotoxic 
potential, or a strong suspicion of human teratogenicity /fetotoxicity  in early  pregnancy  based on 
non-clinical data. GS -6207 has demonstrated/suspected or has insuffic ient data to exclude the 
possibility  of a clinicall y relevant interaction with hormonal contraception that results in r educed 
contraception efficacy . Therefore, contraceptive steroids are not recommended as a contraceptive 
method either solel y or as a part of a contraceptive regimen. Please refer to the latest version of 
the investigator’s brochure for additional information.
b.Contraception Requirements for Female Subjects of Childbearing Potential
The inclusion of female subjects of childbearing potential r
equires the use of highl y effective 
contraceptive measures. Women must also not rely on hormone -containing contraceptives as a 
form of birth control during the study . They  must have a negative serum pre gnancy  test at 
Screening and 
negative urine pregnancy  test at Day 1 prior to first dose of study  drug. Pregnancy  
tests will be performed as defined b y the schedule of assessments in Appendix 2. In the event of 
a delay ed menstrual period (over one month between menstruations), a preg
nancy  test must be 
performed to rule out pregnancy . This is even true for women of childbearing potential with 
infrequent or irregular periods. Female subjects of childbearing potential must ag ree to one of the 
following from Screening until 300 days following the administration of study  drug.
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 100 13 June 2019Complete abstinence from intercourse of reproductive potential. Abstinence is an acceptable 
method of contraception only  when it is in line with the subje ct’s preferred and usual 
lifesty le.
Or
Consistent and correct use of 1 of the following methods of birth control listed below. 
Intrauterine device (IUD) with a failure rate of <1% per year
Tubal sterilization
Essure micro- insert sy stem (provided confirmation of success 3 months after procedure)
Vasectom y in the male partner (provided that the partner is the sole sexual partner and 
had confirmation of surgical success 3 months after procedure)
Female subjects must also refrain from egg donation and in vitro fertilization during treatment 
and until at least 300 days after the administration of study  drug.
3)Contraception Requirements for Male Subjects
It is theoreticall y possible that a relevant s ystemic concentration may be achieved in a female 
partner from exposure of the
male subject’s seminal fluid. Therefore, male subjects with female 
partners must use condoms during treatment and until 360 days after the administration of study  
drug. Additional contraception recommen dations should also be considered if the female partner 
is not pregnant.
Male subjects must also refrain from sperm donation during treatment and until at least 360days 
after the administration of study  drug.
4) Unacceptable Birth Control Methods
Birth cont rol methods that are unacceptable include periodic abstinence (e.g., calendar, 
ovulation, sy mptothermal, post -ovulation methods), withdrawal (coitus interruptus), spermicides 
only, and lactat ional amenorrhea method (LAM). Female condom and male condom shou ld not 
be used together.
5)
Procedures to be Followed in the Event of Pregnancy
Female subjects will be instructed to notify  the investigator if they  become pregnant or suspect 
that they  are pregnant at any  time during the study or if they  become pregnant wit hin 300 days
after the administration of study  drug. A male subject whose partner has become pregnant or 
suspects she is pregnant during the stud y or within 360 days ofthe male subject’s administration 
of study  drug must report the information to the inve stigator. Instructions for reporting 
pregnancy , partner pregnancy , and pregnancy  outcome are outlined in Section 7.7.2.1 .
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 101 13 June 2019Appendix 7. TAF Pregnancy Precautions (Part B) , Definition for Female of 
Childbearing Potential, and Contraceptive Requirements
1)Definitions
a.Definition of Childbearing Potential
For the purposes of this study , a female born subject is considered of childbearing potential 
following the initiation of pubert y (Tanner stage 2) until becoming post -menopausal, unless 
permanentl y sterile or with medically  documented ovarian failure.
Women are considered to be in a postmenopausal state when they  are >
54years of age with 
cessa tion of previously  occurring menses for > 12 months without an alternative cause. In 
addition, women of an y age with amenorrhea of >12 months may  also be considered 
postmenopausal if their follicle stimulating hormone (FSH) level is in the postmenopausal range 
and they  are not using hormonal contraception or hormonal replacement therapy .
Permanent sterilization includes hy sterectomy , bilateral oophorectom y, or bilateral 
salpingectomy  in a female subject of an y age.
b.Definition of Male Fertility
For the purposes of this study , a male born subject is considered fertile after the initiation of 
puberty  unless permanently  sterile b y bilateral orchidectomy or medical documentation.
2)Contraception Requirements for Female Subjects
a.Study Drug Effects on Pr egnancy and Hormonal Contraception
Data from clinical pharmacokinetic interaction studies of TAF have demonstrated that there is no 
reduction in the clinical efficacy  of hormonal contraception. Non -clinical toxicity  studies of TAF 
have demonstrated no adverse effect on fertility  or embry o -fetal development. However, the data 
on TAF in pregnant wome n is limited or not available. Please refer to the latest version of the 
investigator’s brochure for additional information.
b.Contraception Requirements for Femal e Subjects of Childbearing Potential
The inclusion of female subjects of childbearing potential requires using at least an acceptable 
effective contraceptive measure. They  must have a negative serum pregnancy  test at Screening 
and a negative urine pregnanc y test at Day 1 prior to first d ose of study  drug. Pregnancy  tests 
will be performed as defined by  the schedule of assessments in Appendix 2. In the event of a 
delay e
d menstrual period (over one month between menstruations), a pregnancy test must be 
performed t o rule out pregnancy . This is even true for women of childbearing potential with 
infrequent or irregular periods. They  must also agree to one of the follow ing from Screening 
until 7 day s after the last dose of Biktarvy  during the study .If Biktarv y is not initiated, one of the 
following contraception requirements should be followed until 10 day s after the dose of TAF. 
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 102 13 June 2019Complete abstinence from intercou rse of reproductive potential. Abstinence is an acceptable 
method of contraception only  when it is in line with the subject’s preferred and usual 
lifesty le.
Or
Consistent and correct use of 1 of the following methods of birth control listed below. 
Intrauterine device (IUD) with a failure rate of <1% per y ear
Intrauterine hormone -releasing s ystem (IUS) with a failure rate of <1% per y ear
Tubal sterilization
Essure micro- insert sy stem (provided confirmation of success 3 months after procedure)
Vasectom y in the mal e partner (provided that the partner is the sole sexual partner and 
had confirmation of surgical success 3 months after procedure)
Barrier methods (one female barrier and one male barrier must be used in combination)
■Female barriers: Diaphragm with spermic ide or Cervical cap with spermicide
■ Male barriers: Male condom (with or without spermicide)
Hormonal methods (Female subjects who utilize a hormonal contraceptive as one of their 
birth control methods must have used the same method for at least 3 months pr ior to 
study  drug dosing.)
■Oral contraceptives (either combined or progesterone only )
■Injectable progesterone
■Implants of levonorgestrel
■Transdermal contraceptive patch
■Contraceptive vaginal ring
Female subjects must also refrain from egg donation and in vitro fertilization during treatment 
and until at least 7 day s after the last dose of Biktarvy onthe study .If Biktarvy is not initiated, 
female subjects must also refrain from egg donation and in vitro fertilization after TAF 
administration and until at least 10 day s after the dose of TAF.
GS-6207 and TAF
Protocol GS –US-200-4072 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 103 13 June 20193) Contraception Requirements for Male Subjects
During treatment on the study , male subjects with female partners of chi ldbearing potential 
should use condoms when engaging in intercourse of reproductive potential , and male subjects 
must also refrain from sperm donation.
4)
Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (e.g., calendar, 
ovulation, symptothermal, post -ovulation methods), withdrawal (coitus interruptus), spermicides 
only, and lactational amenorrhea method (LAM). Female condom and male condom should not 
be used together.
5) Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify  the investigator if they  become pregnant at any  time during 
the study , or if they  become pregnant within 7 days of the last dose of Biktarvy  on the study . 
Subjects who become pregnant or who suspect that they are pregnant during th e stud y must 
report the information to the investigator and discuss with the investigator whether to continue 
Biktarv y. Subjects whose partner has become pregnant or suspects she is pregnant during the 
study  must report the in formation to the investigator. Instructions for reporting pregnancy  and 
pregnancy  outcome are outlined in Section 7.7.2.1.